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CHAPTER 1: INTRODUCTION 
1.1 Activation- Induced Deaminase  
 Maintaining sequence fidelity of the genetic information coded in 
deoxyribonucleic acid (DNA) is essential to the development and function of 
organisms because inadvertent sequence changes may result in adverse 
consequences to the cell, daughter cells, and the organism. Accordingly, many 
DNA repair processes have evolved to preserve the genome during normal 
cellular processes such as replication. Although there exists immense pressure 
to protect against genomic instability and corruption of sequence context, 
beneficial programmed alterations to genomic DNA which lead to sequence 
changes do occur in specialized processes of the adaptive immune system. 
Through targeted mutations of the immunoglobulin gene of B cells, activation- 
induced deaminase (AID) equips the adaptive immune system with the capability 
of producing a diverse repertoire of antibodies against an almost infinite number 
of antigens and pathogens. However, this mutagenic potential of AID can also be 
deleterious to B cells if it is ectopically expressed, fostering the possibility for 
genomic instability. The focus of this research is to quantify the DNA lesions 
introduced by AID in normal and cancerous B cell genomes for the first time, and 
track the unfavorable consequences that may arise from the aberrant activity of 
AID which may promote development of B cell lymphomas. 
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1.1.1 The Discovery of AID and its Requirement for Antibody Maturation 
 AID was discovered in 1999 in the murine B cell lymphoma cell line 
CH12F3 (1) which was isolated as a model for class switch recombination (CSR), 
a mechanism required to make the antibody isotype most fit for a specific 
category of antigens (see section 1.2.4 for further details). Specifically, CH12F3 
cells class switch from IgM isotype to IgA when stimulated with a particular 
cocktail of cytokines (CD40L, IL-4, TGF- or ‘CIT’). Honjo and colleagues 
investigated the genes with upregulated expression upon CIT stimulation of 
CH12F3 cells using suppression subtractive hybridization (SSH) (2). This PCR-
based method allowed for the amplification of only complementary DNA (cDNA) 
that differed between the transcriptome of stimulated cells and unstimulated 
cells. AID expression was found to be highly induced only when cells were 
stimulated to undergo CSR.  
 A role for AID in the maturation of antibodies was immediately attractive 
due to its largely restricted tissue expression in activated B cells (2). Critical 
supportive evidence of AID’s role in antibody maturation was the finding that 
CSR and somatic hypermutation (SHM), a second mechanism required for 
antibody affinity maturation (see section 1.2.3 for further details), were both 
abolished in mice with a homozygous deficiency in AID (3). Concomitantly, 
Durandy and colleagues determined that patients with hyper-IgM syndrome 
(HIGM2), where CSR and SHM are found to be defective, had mutations in the 
human gene encoding for AID (4). Thus, AID is indispensable for CSR, SHM, 
and antibody affinity maturation. 
	


1.1.2 AID and the Deamination of Cytosine to Uracil in DNA 
 Honjo et al explored the ability of a GST-AID fusion protein to deaminate 
cytidine in vitro since early sequence alignment studies revealed homology of 
AID to Apolipoprotein-B mRNA editing enzyme catalytic polypeptide-1 (APOBEC-
1, 34% amino acid identity). APOBEC-1 was the only well-characterized 
APOBEC family member at the time (2) and since it was known to be an RNA 
editor that deaminates cytidine to uracil in the mRNA of apolipoprotein-B (5), it 
was logically proposed that AID similarly functioned by editing an unknown 
mRNA substrate to indirectly lead to CSR and SHM. However, this mRNA-editing 
model of AID in adaptive immunity is not supported by the vast majority of 
evidence in the field.   
 The ectopic expression of AID in eukaryotic cells such as hybridomas (6), 
T cells (7), fibroblasts (8), and yeast (9) resulted in mutations at cytosines in their 
genomic DNA. Similarly, ectopically expressing AID in E. coli resulted in 
mutations at cytosines in the genome and AID-dependent mutations were further 
enhanced in E. coli deficient in uracil-DNA glycosylase (UNG), the primary 
enzyme that removes uracils in DNA (10). AID is not naturally present in 
prokaryotes such as E. coli, but its ability to promote mutations in the E. coli 
genome suggested that an mRNA intermediate was unlikely the substrate for AID 
in B cells. Based on these E. coli studies, Petersen-Mahrt et al envisioned a 
model where AID directly deaminates cytosines in DNA to uracil specifically in 
the Ig locus of B cells (see Figure 1). Pathways for SHM and CSR were 
hypothesized to occur from the processing of these uracils by other downstream 




enzymes such as UNG2, error-prone polymerases, mismatch repair (MMR) 
proteins, and AP endonuclease (10).   
Figure 1: AID Dependent Hydrolytic Deamination of Cytosine to Uracil 

Figure 1: AID Dependent Hydrolytic Deamination of Cytosine to Uracil. AID 
catalyzes the nucleophilic attack of a water molecule at the C4 position of 
cytosine. The loss of the amino group as ammonia, results in the formation of 
uracil. Figure created in ChemBioDraw Ultra 14.0. 
 
 
 Several groups provided biochemical evidence that supports DNA, 
specifically single-stranded DNA or single-stranded regions in transcribed 
double-stranded DNA, as the substrate for AID cytosine deamination. AID was 
shown not to deaminate cytosines in RNA, non-transcribed double-stranded 
DNA, or DNA-RNA hybrids (11-14). Furthermore, in vitro studies determined that 
the hotspot for AID deamination is a cytosine occurring in a WRC motif (where W 
is an A or T, R is a purine, ie G or A) (15). This is in agreement with the WRC 
SHM hotspot motif determined in vivo (15). Substantial evidence in the field has 
predominantly supported the direct ‘DNA-editing model’ of AID at the Ig gene, 
and thus this model prevails over the originally proposed ‘mRNA editing model’. It 
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is widely accepted that AID catalyzes the hydrolytic deamination of 2’-
deoxycytidine (C) to 2’-deoxyuracil (U) in a sequence context specific manner 
and prefers single-stranded DNA regions in the Ig gene (see Figure 1) (16). 
Figure 2: The Primary Structure of AID 
 
Figure 2: The Primary Structure of AID. AID is found on human chromosome 
12 and has 5 exons. The gene codes for a 198 amino acid protein. The primary 
structure of AID is depicted above with major domains of the protein highlighted. 
AID has an amino terminal nuclear localization signal (NLS), and a carboxy 
terminal nuclear export signal (NES). The catalytic domain is required for both 
somatic hypermutation (SHM) and class switch recombination (CSR). Catalysis 
of the hydrolytic deamination of C to U depends on the glutamate residue at 
position 58 (E58) for acid-base catalysis, and the histidine at residue 56, and 
cysteines at positions 87 and 90 (H56, C87, and C90 respectively) for zinc 
coordination to activate a water molecule. The C-terminus of the protein is 
required for CSR while the N-terminus is required for SHM.  
 
1.1.3 AID and Subcellular Localization 
 The gene encoding AID has five exons and is located in close proximity to 
the APOBEC-1 gene on the same chromosome in both mice (chromosome 6) 
and humans (chromosome 12). As described above, the catalytic domain or zinc 
coordination motif of AID is conserved with other members of the APOBEC 
family of proteins. Mutation of the glutamate residue at position 58 (E58) in the 
catalytic domain of AID can result in a catalytically inactive mutant (see Figure 2). 
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E58 is thought to participate in general acid-base catalysis and residues H56 
(histidine), C87 and C90 (cysteine) coordinate with a Zn2+ along with an activated 
water molecule to mediate nucleophilic attack of the carbon-4 of cytosine, 
promoting deamination or loss of the amino group (see Figure 3) (16, 17). This 
catalytic domain of AID is required for both in vivo SHM and CSR. 
 With a functional catalytic domain intact, mutational experiments of AID 
revealed that the carboxy-terminal (C terminal) domain of the AID protein (198 
amino acids, ~24 kDa) is necessary for CSR, while the aminoterminal (N 
terminal) domain is required for only SHM (18-20). The C and N terminal 
domains also play a role in the subcellular localization of AID. Since AID acts on 
genomic DNA of activated B cells, nuclear localization is required. However, 
because of its mutagenic potential, AID is actually a nucleocytoplasmic shuttling 
protein (21). A nuclear export signal NES is located in the last ~10 residues of 
the C terminal domain (22-24) while a nuclear localization signal (NLS) was 
identified encompassing most of the N terminal domain (see Figure 2) (22, 25). 
Recent work has also demonstrated that subcellular compartmentalization of AID 
also depends on active cytoplasmic retention which may afford overall genomic 
protection from this DNA mutator enzyme (25). 
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Figure 3: Proposed Mechanism of AID Catalyzed Deamination of Cytosine 

Figure 3: Proposed Mechanism of AID Catalyzed Deamination of Cytosine. 
The catalytic pocket of AID contains the glutamate residue at position 58 (Glu58) 
which participates in general acid-base catalysis for the activation of a water 
molecule. Cysteines at positions 87 and 90 (Cys87, Cys90) and histidine 56 
(His56) coordinate a zinc along with the water molecule. The remaining hydroxyl 
group serves as a nucleophile to attack the C4 position of a cytosine, yielding an 
intermediate that eventually gives rise to uracil once an ammonia group leaves. 
The proposed mechanism shown above for AID is based on homology with 
cytidine deaminases and mutational studies (16, 17, 26). Figure created in 
ChemBioDraw Ultra 14.0 
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1.2  The Role of AID in the Adaptive Immune System 
  The immune system of vertebrates is composed of innate immunity and 
adaptive immunity (27). Innate immunity is the immediate line of defense and is 
nonspecific towards the antigen. Anatomical barriers such as mucosal and 
epithelial surfaces, inflammation, and broad recognition of pathogen-associated 
molecular patterns (PAMPs) by particular cells of the immune response system, 
define this branch of innate immunity (28). However, innate immunity does not 
offer long-term protection or ‘memory’ against previously encountered antigens 
but plays a role in the activation of adaptive immunity. This second branch of the 
immune system, also referred to as acquired immunity, is antigen-specific and 
has the ability to confer immunological memory. AID plays a role in producing 
antibodies required for an appropriate adaptive immune response. 
1.2.1 The Structure and Function of Immunoglobulins 
 Antibodies, or immunoglobulins, are either expressed on the surface 
membrane of B cells as B cell receptors (BCR) or are secreted by plasma cells, a 
specific type of differentiated B cell (28). Immunoglobulins are glycoproteins with 
a base unit of a homodimer of a heterodimer (27). The heterodimer is comprised 
of a longer ‘heavy’ polypeptide chain and a shorter ‘light’ chain. Disulfide bonds 
bridge the heavy chain and light chain of the heterodimer as well as the 
homodimer (see Figure 4A). There are two antigen binding pockets, or variable 
domains, in the base unit of antibodies (see Figure 4A).  Mutations from SHM 
produce antibodies with different primary sequences for their antigen sites, hence 
‘variable domain,’ to confer high affinity against antigen (see Figure 4B, and 
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Figure 5B). In contrast, CSR or lack thereof, determines the constant domain of 
the immunoglobulin (see Figure 4C and Figure 6). The final antibody structure 
can be secreted as a monomer, dimer, or even hexamer of this base unit 
depending on the isotype (ie. IgM can form a pentamer with ten antigen binding 
sites).   
Figure 4: Structure of Immunoglobulins 
 
 
Figure 4: Structure of Immunoglobulins. (A) Immunoglobulins, or antibodies, 
consist of a base unit of a homodimer of a heterodimer. The heterodimer consists 
of the ‘heavy’ polypeptide chain and the shorter ‘light’ chain. Thus, the 
homodimer has two heavy and two light chains as depicted. Disulfide bonds 
bridge the heterodimer and the homodimer. There are two antigen binding 
pockets, or variable domains, in the base unit of antibodies. (B) Somatic 
hypermutation occurs when AID introduces mutations that alter the variable 
regions of the Ig gene to produce higher affinity antibodies for specific antigen, 
indicated here as a change in shape of the antigen binding pockets to fit the 
antigen more appropriately. (C) Class switch recombination occurs when AID 
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introduces double strand breaks that eventually lead to juxtaposition of a new 
constant domain downstream of the variable region resulting in a gene that 
codes for a new isotype. CSR is depicted here as a change in color of the 
constant heavy chain from IgM (purple) to IgE (pink). 
 
 High affinity immunoglobulins not only neutralize foreign pathogens but 
are also essential in activating several other immune responses to combat 
infection. The different isotypes of antibodies (IgM, IgD, IgG, IgA, and IgE) are 
coded by the different constant regions in the heavy chains of the Ig gene (Cµ, 
Cδ, Cγ, Cα, and Cε respectively and see Figure 6). CSR is designed to yield the 
immunoglobulin isotype that is best equipped to eradicate the specific pathogen 
based on the nature of the antigen and the ability of the antibody to reach the 
tissue site of the infection. For example, since IgM is secreted as a large 
pentamer or hexamer, it cannot traverse into extravascular space. This makes it 
unsuitable to neutralize antigens distributed in that tissue, in contrast to 
monomeric IgG. In addition, antibodies are switched to the isotype best able to 
eradicate the specific pathogen type. For example, IgE is suited for parasitic 
infections (29) and IgA is effective against mucosal bacteria (30).   
1.2.2 Antibody Affinity Maturation 
 The initial expansion of the antibody repertoire arises from the process of 
V(D)J recombination which is both independent of available antigen and T-cells, 
and does not require AID. This is a combinatorial process that occurs early in B 
cell development to establish a variable region through rearrangements of the 
variable (V), diversity (D) and joining (J) segments in the Ig gene (31, 32). 
Further expansion and diversification of the antibody repertoire is achieved by 
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SHM and CSR which are antigen-dependent processes that continue to alter the 
Ig gene and as described above, absolutely require AID. All three processes are 
essential for antibody maturation. 
Figure 5: SHM of the Variable Region of the Immunoglobulin Gene  
 
 
Figure 5: SHM of the Variable Region of the Immunoglobulin Gene. (A) A 
truncated immunoglobulin gene (heavy chain) with a rearranged V(D)J region is 
schematically depicted. The variable region, V(D)J, is depicted in blue. The 
enhancer (E), switch region (S), and constant domain (C) that codes for IgM 
(purple) is downstream of the variable region. Thus, without class switching, the 
default encoded Ig isotype is IgM. The Sε and Cε (pink) are the respective switch 
region and constant domain for the IgE isotype, and Sα and Cα (orange) are the 
switch and constant domains for the IgA isotype. The 3’ Regulatory Region 
(3’RR, red) is composed of enhancers that promote efficient CSR (33) and SHM 
(34). (B) Somatic hypermutation occurs when AID-dependent point mutations, 
depicted as yellow bars, are introduced in the V(D)J region of the Ig gene. AID 
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acts on single-stranded DNA during transcription and the V(D)J transcription start 
site (TSS) is shown as a red arrow. 
 
Figure 6: Class Switch Recombination 
 
 
 
Figure 6: Class Switch Recombination. Elements of the Ig gene are depicted 
similar to that in Figure 5. (A) Before CSR, the Ig gene codes for an IgM 
transcript. Upstream of each constant domain is a switch region, S, that is 
transcribed from an intronic promoter (red arrows) since AID requires 
transcription. When class switching from IgM, the default coded constant region, 
to another isotype, AID deaminates cytosines to uracils in S and Sdownstream.  
Sdownstream  in this case is Sε. (B) Through the excision of uracil by UNG, nicking of 
the AP site by APE, and error prone BER or MMR, double strand breaks (DSBs, 
green arrows) are introduced. (C) Upon resolution of the DSBs by non-
homologous end joining or alternative end-joining (not shown), an S and Sε 
synapsis brings the Cε region downstream of the V(D)J which allows for the 
coding of IgE. The intervening DNA region which contains the C domain is 
ligated into a ‘switch circle’ and deleted. 
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 Post V(D)J recombination, AID introduces point mutations within the 
rearranged V(D)J segments of the Ig gene in B cells during SHM (see Figure 5B) 
(2-4, 35). Those B lymphocytes which attain somatic mutations that improve 
antibody affinity for the antigen are positively selected for while those B cells that 
acquire mutations that reduce affinity of the antibody for the antigen are removed 
from the B cell population via programmed cell death. This clonal selection allows 
for the evolution of progressively higher affinity antibodies with each continuous 
and iterative step of SHM (see Figure 7 Clonal selection) (36, 37).  
Figure 7: Clonal Selection of High-Affinity Antibodies 
 
 
Figure 7: Clonal Selection of High-Affinity Antibodies. Naïve B cells (clones 
1,2, and 3) having undergone V(D)J recombination express different surface 
antibodies (Ab). Only the Ab on the surface of clone 3 has some affinity to a 
specific antigen (Ag, blue rectangle). Through receptor binding, T cells recognize 
this Ab-Ag complex and mediate clonal expansion by promoting proliferation of 
clone 3. SHM and CSR help produce high affinity Abs and the correct isotype 
needed for the specific antigen. Clones that acquire mutations during iterative 
rounds of SHM and Ag exposure (circular arrow) that result in reduced or poor 
affinity Abs undergo programmed cell death, while those that acquire beneficial 
1 
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mutations expand. ‘Clone 4’ has class switched and has a high affinity Ab to the 
specific Ag. Figure created in ChemBioDraw Ultra 14.0 
 
 CSR is a programmed DNA recombination process that yields the most 
effective antibody isotype needed during each immune response (35, 38). During 
CSR, the rearranged variable region is joined with one of several different 
downstream constant regions (ie Cα, Cγ, Cε) that each confer a specialized 
optimal effector function. Switch (S) regions which contain short repetitive 
sequences are located upstream of the constant regions in the Ig genes (see 
Figure 6). Following AID-dependent introduction of double-strand breaks in Sµ 
and a second downstream S region, the intervening sequence is circularized and 
deleted while the two different S regions are joined together (39). This juxtaposes 
the V(D)J exon to a downstream constant region exon that results in isotype 
switching from IgM to IgA, IgG, or IgE (see Figure 6 for a schematic of IgM to IgE 
isotype switching). 
 In addition to SHM and CSR, some vertebrates evolved a third AID-
dependent mechanism of antibody affinity maturation known as gene conversion 
(GCV) (40, 41). In species, such as chicken, pigs, and rabbits, GCV is the 
dominant method of V segment diversification (42, 43). This process does not 
take place in the biological systems studied in this work, mice and human B cells, 
and thus will not be discussed in detail here. 
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1.2.3 The Mechanism of Somatic Hypermutation  
1.2.3a Mutational Characteristics of the Immunoglobulin Gene and SHM 
 During SHM, AID introduces mutations in the variable segment of the 
heavy chain of the Ig gene in activated B cells, with the highest occurrence of 
mutations found in the exons of the V(D)J segment. In addition mutations are 
acquired in the introns of the J regions as well. However, AID avoids mutating the 
C domain genes. The promoter regulatory regions and an enhancer element 
located in the intron also evade AID induced mutations (see Figure 8) (44, 45).  
Figure 8: Intensity and Boundaries of SHM in the Variable Region 
 
Figure 8: Intensity and Boundaries of SHM in the Variable Region. The level 
of the mutation frequency (y axis) of the immunoglobulin heavy chain is 
schematically (not to scale) depicted along the regions of the Ig gene (x axis). 
The transcription start site (red arrow) begins at the promoter (P). Somatic 
hypermutations are found approximately 100 to 200 base pairs downstream from 
the TSS(46) with the highest accumulation of mutations found within the V(D)J 
region. The mutations accumulate up to approximately 1500 base pairs 
downstream of the TSS (47). The enhancer and constant domain (Eµ and Cµ, 
respectively) do not undergo SHM. Adapted from figures in references (46, 48). 
Features of Somatic Hypermutation 
of the Variable Region 
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SHM may occur in switch regions as well but is not shown or discussed here 
(48). 
 
 Mutations in SHM are predominantly found in the form of single base 
changes, or ‘point mutations,’ and accumulate approximately 100 to 200 base 
pairs (bps) from the transcription start site (TSS) with the mutation spectrum 
extending up to approximately 2.0 kb downstream of the TSS (44-46, 49, 50). 
Furthermore, in SHM, most of the point mutations are transitions (e.g. pyrimidine 
mutated to a pyrimidine, purine mutated to a purine) rather than transversions 
(e.g. pyrimidine mutated to a purine and vice versa). Since AID has sequence 
selectivity, it is not surprising that many mutations in the V(D)J segment are 
targeted to the WRC hotspot motif (15, 47, 51).  
 The frequency of SHM mutations is approximately 106 fold higher than that 
for background genomic mutations- the V(D)J segment can accrue roughly 10-3 
mutations per base pair per generation (16). High SHM mutation frequency in the 
variable region also correlates with high transcription levels (52). SHM requires 
transcription, but transcription alone is not sufficient to ensure AID activity. 
Transcription is thought to provide the single-stranded DNA substrate needed by 
AID, in the form of a ‘transcription bubble’ (53). SHM is not strand biased, with a 
similar mutation frequency seen in both the template strand (TS) and the 
nontemplate strand (NTS) (54). 
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1.2.3b Error-Free Base Excision Repair of Uracils 
 Simple direct replication across from an AID-introduced uracil will 
eventually produce a G/C transition mutation after a second round of replication 
(see Figure 9 Upper Right) (10). The replicating DNA polymerase will insert an A 
across from a template U, effectively treating the DNA lesion as a template T. 
The mutations of SHM are not just C to T transition mutations and not restricted 
to G/C bases but occur just as efficiently at A/T base pairs in SHM. Thus, simple 
replication cannot be the only mechanism in activated B cells that leads to a 
hypermutated Ig gene.  
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Figure 9: Model of Somatic Hypermutation of the Variable Region 
 
 
Figure 9: Model of Somatic Hypermutation of the Variable Region. AID 
deaminates C to U in the V(D)J region of the Ig gene of B cells. The resulting 
U•G mispair can be processed in several ways. (Upper Right) Replication past a 
U will result in the insertion of an A, eventually resulting in a C to T transition 
mutation in one daughter cell after a second round of replication. (Lower Right) 
Uracil DNA-glycosylase (UNG) can excise the uracil resulting in an AP site that 
can be bypassed by error-prone translesion synthesis polymerases (TLS). These 
polymerases may insert any of the four nucleotides resulting in C to N mutations. 
(Middle) Canonical base excision repair (BER) depends on the excision of U by 
UNG, nicking of the AP site by APE, and pol and ligase to correctly restore the 
C:G base pair. (Left) Mismatch repair (MMR) proteins, specifically MSH2/6, 
recognize the U•G mispair.  Exonuclease 1 helps to create a gap around the 
initial U lesion and TLS polymerases are then recruited and insert any of the four 
nucleotides throughout the excised gap. This results in transition and 
transversion mutations at A:T and G:C base pairs. 
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 The evolution of antibody affinity maturation which promotes mutations of 
the Ig gene requires more than just AID, a targeted DNA mutator. It also requires 
evolution of downstream pathways to ensure the AID generated uracils are not 
simply excised and repaired by the several highly conserved DNA damage repair 
systems in place to protect genomic instability. To circumvent error-free repair of 
the uracils, many enzymes involved in canonical genomic uracil repair pathways 
have been hijacked to play counter-intuitive roles in activated B cells to ensure Ig 
gene mutations. 
 Since uracil is introduced into genomes by pathways other than the 
enzymatic deamination of cytosines by members of the AID/APOBEC family of 
proteins, highly conserved DNA repair pathways have evolved to remove and 
excise genomic uracils, restoring sequence context. The misincorporation of 
uracil during replication, and the non-enzymatic spontaneous deamination of 
cytosine to uracil, both result in uracilated DNA. Uracil generated through 
misincorporation of a dUMP occurs when the replicating polymerase uses dUTP 
as a substrate rather than dTTP (see Figure 10 for details). This results in U:A 
base pairs that are not directly mutagenic. In contrast, spontaneous deamination 
of a cytosine in a C:G base pair results in a U•G mispair that can lead to a C to T 
mutation if unrepaired and replicated past, similar to consequences from AID 
deaminated cytosines (see Figure 11). 
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Figure 10: Pathways for Uracil Incorporation in DNA 

Figure 10: Pathways for Uracil Incorporation in DNA. (A) Uracil can be 
misincorporated into DNA during replication. Generally, this is avoided by actively 
keeping the dUTP pool low due to dUTPase (deoxyuridine 5’ triphosphate 
nucleotide-hydrolase). As depicted above, dUTPase hydrolyzes dUTP to dUMP 
(and pyrophosphate, not shown). Thymidylate synthase reductively methylates 
dUMP during de novo synthesis of dTMP. dTMP is then converted to dTTP which 
is a substrate for DNA polymerase (DNA pol) during replication. dUMP is 
produced from the deamination of dCMP by DCD (deoxycytidylate deaminase). 
In addition, RNR (ribonucleotide diphosphate reductase) converts UMP to dUDP 
which is then phosphorylated to dUTP. DNA pol is able to use available dUTP as 
a substrate and inserts uracil across from a template A during replication. (B) 
Uracil can also occur in DNA through hydrolytic non-enzymatic spontaneous 
deamination of cytosine as depicted. Cytosines can also be deaminated 
chemically, for example by bisulfite(55) and nitrous anhydride(56) (not shown). 
Figure created in ChemBioDraw Ultra 14.0 
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Figure 11: Mutational Consequences of Uracil in DNA 
 
 
Figure 11: Mutational Consequences of Uracil in DNA. (A) The 
misincorporation of dUMP instead of dTMP by DNA polymerase (DNA pol) yields 
a U:A base pair. When this undergoes replication (Replication 1) a normal T:A 
base pair is generated and an A is inserted across from the U in the top strand. A 
second replication event (Replication 2) also results in normal T:A base pairs and 
further dilutes the non-mutagenic U:A base pair until it can be excised and 
repaired. (B) Deamination of cytosine to uracil, whether spontaneous or 
enzymatic is mutagenic.  This results in a U•G mispair. Replication past this 
(Replication 1) results in a U:A base pair as well as a C:G base pair. Another 
replication event (Replication 2) fixes a C to T mutation (green star).  



Figure 12: Uracil DNA-Glycosylase 
 

Figure 12: Uracil DNA-Glycosylase. Uracil DNA-Glycosylase (UDG) recognizes 
uracil in single-stranded DNA, or in U:A and U•G pairs. Through hydrolysis of the 
N-glycosidic bond, UDG excises uracil from DNA. This results in the formation of 
an AP site, or abasic site, and the release of free uracil and is the first step in 
base excision repair. Figure created in ChemBioDraw Ultra 14.0 
 
 The faithful process of base excision repair (BER) (see Middle, Figure 9) 
maintains the integrity of DNA by removing and repairing various lesions and 
adducts through a multiple-step pathway. Canonical BER is initiated by the 
excision of the DNA lesion by DNA glycosylases capable of recognizing and 
excising DNA adducts through hydrolysis of the N-glycosidic bond. Thus, uracils 
are removed by uracil-DNA glycosylases (see Figure 12) There are four types of 
uracil-DNA glycosylases (UDG or UNG) in mammalian systems which include 
UNG,single-strand specific monofunctional uracil-DNA glycosylase 1 (SMUG1), 
thymine-DNA glycosylase (TDG), and methyl-CpG binding domain protein 4 
(MBD4) (57, 58). The mammalian UNG gene encodes the two existing isoforms 
of UNG, mitochondrial UNG1 and nuclear UNG2 (59). The evolution of several 
redundant glycosylases with the ability to remove genomic uracil highlights the 
selective pressure against uracils accumulating in the genome. TABLE 1 lists all 
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the different DNA lesions in the context they are recognized in by the individual 
glycosylases capable of removing uracils. UNG2 is the major glycosylase 
responsible for removal and initiating repair of genomic uracil with SMUG1 
thought to be the primary back-up enzyme (57, 60).  
TABLE 1: Substrates of the Human Uracil DNA Glycosylases 
 
                     TABLE 1: Human Uracil DNA Glycosylases are indicated with    
                     substrates shown in bold.  
 
 Upon recognition of uracil, UNG2 cleaves the N-glycosidic bond to release 
free uracil base generating an abasic site (AP) in the DNA. AP endonuclease 
(APE) then nicks the AP site. The deoxyribophosphodiesterase (dRPase) activity 
of DNA polymerase β (Polβ) cleaves the 3' end of the nicked abasic site and 
releases deoxyribose-5-phosphate (dRP). Polβ then inserts the correct base 
according to the template- a C to restore the C:G base pair if the uracil resulted 
 
Glycosylases 
 
Substrates 
 
References 
 
UNG1/UNG2 
 
 
U in ssDNA 
U:A 
U•G 
 
 
 
 
(61) 
 
 
 
SMUG1 
U in ssDNA 
U:A 
U•G 
5hmU in ssDNA 
5hmU:A 
5FU:A 
 
 
 
 
(62, 63) 
 
TDG 
 
 
T•G 
U•G 
εC:G 
 
 
(64) 
 
MBD4 
 
 
 
T•G 
U•G 
 
 
 
(65) 
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from deamination or a T to restore the T:A base pair if the uracil was 
misincorporated during replication. DNA ligase then seals the nick to complete 
what is termed ‘short patch’ BER, the removal of only the uracil base and the 
insertion of one correct nucleotide (see Figure 9 Middle). ‘Long-patch’ BER 
involves the replicative machinery and polymerases, flap endonuclease-1 
(FEN1), and removal and repair of a gap of ~ 2 to 10 nucleotides to repair the 
uracil lesion (66). Contradictory to their primary roles, during SHM of activated B 
cell, UNG2 and APE function to promote mutations. 
1.2.3c Error-Prone Resolution and UNG2 in SHM 
 Similar to patients deficient in functional AID protein with HIGM2 
syndrome, mutations in the human UNG2 gene result in a similar disorder termed 
HIGM5 where their antibodies are also compromised in SHM and CSR (67, 68). 
The introduction of mutations during SHM is dependent on UNG2 for removal of 
the AID induced uracil and generation of an AP site (69, 70). UNG2 is primary for 
shaping the mutational spectrum of SHM at G/C base pairs. While mutations at 
A/T base pairs occur during SHM, they seem to be predominantly dependent on 
a different repair pathway (see section 1.2.3d).  
 UNG2 excises uracils introduced in the variable region of the Ig gene by 
AID similar to the first step of error-free BER. Since the resulting AP sites have 
no instructive base, they cannot be bypassed by replicative polymerases and 
thus, error-prone translesion synthesis polymerases (TLS) are recruited. These 
polymerases  are capable of bypassing the AP site (71) since the promiscuous 
nature and more permissive binding site of the TLS polymerases allows for the 
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insertion of any of the four nucleotides across the AP site. This results in G/C 
transitions and transversions during SHM (72) (see Figure 9).  
1.2.3d Mismatch Repair and A/T Mutations in SHM 
 Replicative polymerases are equipped with proofreading capabilities to 
correct mismatch errors that may occur during insertion of an incorrect dNMP. 
However, if a replication error escapes detection as well as correction by the 
replicative polymerase, a highly conserved repair pathway is available for 
recognition and repair of the mismatched base pair to avoid mutations. This 
pathway termed mismatch repair (MMR), is a multi-step process which depends 
on several proteins for the recognition, removal, and repair of the DNA as well as 
complex interactions with the DNA replication machinery (73, 74). Not unlike the 
BER pathway, some MMR proteins have also been exploited to actually promote 
mutations in the Ig gene of activated B cells. Only MMR proteins relevant to 
antibody affinity maturation will be discussed. 
 MMR proteins were initially discovered to affect SHM in studies of mice 
deficient in MutSα, a complex consisting of the factors MSH2 and MSH6 that are 
required for recognition of non- Watson-Crick base pairs. The majority of 
hypermutations at A/T base pairs in the activated B cells were reduced by ~85% 
(75, 76). MutSα recognizes the AID generated U•G base pair in the variable 
region and an endonuclease is thought to make an incision 5’ to the mismatch. 
This allows Exonuclease 1 (Exo-1) to degrade the DNA and generate a gap 
around the initial uracil lesion. Exonuclease 1 is responsible for generating a gap 
in the strand with the misincorporated base during normal MMR, and performs a 
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similar role in promoting A/T base pair mutations during SHM (77). Recent 
evidence suggests that in germinal center B cells, nicking of AP sites by APE2 
may provide an accessible end for Exo-1 (78, 79). A large gap is required to 
avoid confining mutations to just the initial AID lesion and allows for more 
mutations around the original deaminated cytosine. Finally, as in UNG2 
dependent mutations in SHM, it is TLS polymerases that are recruited and fill in 
this gap in an error-prone manner, creating transitions and transversions at A/T 
base pairs (see Figure 9). 
 The majority of A/T mutations in SHM are dependent on MMR recognition 
factors, but ~15% can still be found in the Ig genes of activated B cells of MutSα 
deficient mice. However, complete ablation of A/T mutations occurs in mice that 
are deficient in both UNG2 and MSH2 (69, 80). Similar results are seen in mice 
deficient in UNG2 and MSH6 (81). This supports a secondary role for UNG2 in 
generating a minority of the A/T transitions and transversions around the original 
uracil lesion and it is proposed that error-prone long-patch BER may be involved. 
   
1.2.4 The Mechanism of Class Switch Recombination 
 AID is required to initiate CSR, but unlike SHM, the uracils generated are 
not processed to promote mutations. Instead, AID induced uracils during CSR 
are converted to double-strand breaks (DSBs), and then resolved to adjoin the 
variable segment of the Ig gene to a new constant domain, with the intervening 
sequence circularized and degraded. Similar to SHM, however, is that this 
deletion-recombination event depends on BER and MMR proteins to promote 
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genomic instability, contrary to their ubiquitous primary roles in protecting the 
genome. 
1.2.4a Switch Regions and CSR 
 Downstream of the V(D)J segment of the Ig gene are the constant 
domains which code for the effector functions of the antibody (see Figure 5A and 
6). Directly upstream of each constant domain, with the exception of Cδ, is a 
switch region (S). Each S region has an upstream ‘intronic’ or ‘intervening’ (I) 
exon with its own promoter. Since AID requires transcription, the I exon and its 
associated promoter ensure transcription through the S region and thus allow for 
targeting of the S region by AID (82). The induction of transcription of different I 
exon promoters are cytokine or cytokine cocktail specific to stimulate class 
switching to different constant domains, and thus effector functions, as needed. 
For example, stimulation by interleukin-4 (IL-4) can induce germline transcription 
of the Iε, ensuring access of AID to the S region directly upstream of Cε, and thus 
allow for switching from the default IgM to IgE (83, 84). This transcription 
produces a germline transcript (GLT) which is considered a ‘sterile’ transcript, as 
it lacks an open reading frame and is not translated (82). GLTs are essential to 
CSR (85).  
 As targets of AID, it is not surprising that S regions contain frequent AID 
hotspot motifs (ie WRC). For example, the core of the switch region contains 5ʹ-
AGCT-3ʹ repeats and this motif is highly enriched in the S regions compared to 
the rest of the genome (86). Furthermore 5ʹ-AGCT-3ʹ sequences ensure a WRC 
AID deamination motif in both DNA strands (87). S regions are also characteristic 
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of containing a NTS enriched with G nucleotides. These clusters of G nucleotides 
promote the formation of R-loops where the transcribed mRNA strand hybridizes 
with the TS of DNA.  This causes displacement of the NTS and allows a single 
stranded DNA loop of potentially hundreds of nucleotides to form (88). Thus, 
WRC motifs, R-loops, and GLT ensure S regions are a welcoming DNA substrate 
for AID.  
1.2.4b AID Promotion of Double-Strand Breaks  
 During CSR, AID introduces uracils in the S region as well as the 
downstream S region (Sdownstream) that has been upregulated for transcription 
upon response to stimulation with specific cytokines. In class switching to IgE, for 
example, AID introduces uracils in the downstream Sε region, but effective CSR 
depends on a complex of proteins forming at the S regions. Particularly, AID is 
recruited to the 5ʹ-AGCT3ʹ enriched S regions by 14-3-3 adaptor proteins to 
allow for deamination of cytosines. The TLS polymerase Rev1 recruits UNG2 to 
excise AID generated uracils. Evidence supports Rev1 plays only a scaffolding 
role, bringing UNG2 to the S regions, since CSR is independent of Rev1 
enzymatic activity (89). 14-3-3 adaptor proteins have also been shown to directly 
interact with and stabilize UNG2 at the S region (90). The AP sites, resulting from 
UNG2-excision of uracils, are nicked by APE1 and form SSBs (91). In addition to 
APE1, lyase activity of MRE11–RAD50 may also process and cleave AP sites 
(92). 
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  Since AID activity is not strand biased, and WRC motifs occur in close 
proximity on both strands, AP sites and therefore nicks are generated in both the 
TS and NTS promoting direct DSB formation in the S regions. MMR proteins, 
including MutSα and Exo-1, also help to produce DSBs in the flanking regions. 
The AID dependent DSBs created in both S and Sdownstream are resolved by 
classical non-homologous end joining (c-NHEJ) or alternative-end joining (A-EJ) 
(84). Finally the intervening sequence is excised and circularized. This ‘switch 
circle’ is eventually degraded. Thus, the V(D)J segment is juxtaposed to the S-
Sdownstream junction and allows for class switching to the new constant domain 
(see Figure 6 for a schematic of IgM to IgE class switching). 
1.3 The Role of AID in Lymphomagenesis 
 AID is a DNA mutator enzyme and its ectopic expression may play a role 
in the transformation of tissue from hepatocytic, gastric, mammary, and oral 
epithelial origin (93-97). Despite the tight regulation of subcellular localization, Ig 
gene targeting, and restricted B cell spatiotemporal expression, it is not 
unexpected that AID is proposed to have a role in the development of germinal 
center (GC) B cell lymphomas. The GC microenvironment promotes AID 
dependent mutations and DSBs in the Ig gene. However, aberrant SHM or CSR 
at non-Ig genes can be deleterious to the activated B cells leading to cancer. 
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1.3.1 The Germinal Center Reaction  
 AID is primarily targeted to the Ig genes of B cells and is found highly 
expressed in B cells exposed to antigen and undergoing antibody maturation (2, 
3). The upregulation of AID and antibody maturation occurs in the germinal 
centers (GC) which are temporary microenvironment structures essential to the 
immune response that develop upon exposure to antigen. They are located in 
secondary lymphoid tissues such as the spleen and lymph nodes (84, 98, 99). 
GCs foster an environment of collaboration between specialized immune cells 
with the primary function of generating B cells with high-affinity antibodies. Thus 
the “germinal center reaction” (GC-reaction) requires upregulation of AID and the 
processes of SHM and CSR (98).  
Figure 13: The Germinal Center Reaction 
 
 
Figure 13: The Germinal Center Reaction. Post V(D)J recombination, 
precursor B cells develop into naïve B cells that have not been exposed to 
antigen. After exposure to antigen, germinal centers are formed in secondary 
lymphoid structures such as the spleen and lymph nodes, and have two 
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histologically identifiable regions, the ‘dark zone’ (DZ) and the ‘light zone’ (LZ). 
AID-dependent SHM and CSR occur in the GC-reaction. This leads to mutations 
and class switching in order to form high affinity antibody producing B cells. 
These will differentiate into plasma cells and memory B cells. However, not all 
mutations accumulated during the GC-reaction are beneficial and thus, these B 
cells undergo apoptosis as depicted above. Some AID-dependent mutations or 
translocations acquired during the GC-reaction may be deleterious ( ) and 
promote lymphomagenesis. 
 
 Prior to antigen exposure, the only diversification event that occurs in 
antibodies is V(D)J recombination in B cells early in development (pro- and pre-B 
cells). This takes place in the primary lymphoid tissue of the bone marrow. V(D)J 
recombination alone does not result in high affinity antibodies. Before GC 
development, secondary lymphoid organs are found to contain primary follicles 
which consist of predominantly naïve B cells that have not been subjected to 
interaction with antigen. Post antigen-exposure, however, GCs begin to form 
within the primary follicles and thus, force the naïve B cell population to the 
periphery of the follicle and form the region termed the B cell mantle (36). Early 
GCs are separated into ‘dark zones’ (DZ) and ‘light zones’ (LZ) which are 
histologically visible divisions (see Figure 13 for a schematic overview) (99, 100). 
The DZ primarily contains B cells exposed to antigen, ‘activated’ B cells, that 
express high levels of AID (or centroblasts) and undergo SHM and CSR (36, 
101) while the LZ has antigen-selected GC B cells (or centrocytes) which also 
express AID and can undergo CSR. LZs also contain specialized cells which 
participate in the presentation of antigens to B cells and their development. 
These include follicular dendritic cells (FDCs) CD4+ and CD8+ T cells and 
tingible-body macrophages (TMϕs). TMϕs are a specific type of macrophage that 
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phagocytose B cells undergoing apoptosis during clonal selection in the GC 
reaction (102, 103).   
 Once GC B cells have acquired antibodies with high affinity against the 
antigen, they can exit the GC and differentiate into antibody secreting cells 
known as plasma cells to help eradicate the current infection. Other GC exiting B 
cells will differentiate into memory B cells to provide for a more rapid and long-
term immunological response against a second future exposure to the antigen. 
The GC reaction is essential to the adaptive immune system. However, this 
process of promoting AID-induced mutations and strand breaks in DNA for 
antibody affinity maturation bears considerable risks in the form of inadvertent 
oncogenic mutations and translocations.  
1.3.2 Features of B Cell Lymphomas  
 The translocation of the Ig gene with a proto-oncogene is characteristic of 
many types of B-cell lymphomas. This deleterious chromosomal rearrangement 
may result in the constitutive expression of the oncogene as it comes under the 
transcription regulation of the Ig gene due to its juxtaposition (104-106). Studies 
have demonstrated that AID is essential for the formation of the c-Myc-IgH 
translocation found in specific B cell lymphomas (107, 108). Aberrant CSR is 
thought to be the culprit, where DSBs in the Ig are incorrectly adjoined to DSBs 
in the c-Myc oncogene from mis-targeting of AID, resulting in a reciprocal 
translocation. The transformative potential of Ig-oncogene translocations in B cell 
lymphomas has long been ascertained, pre-dating the discovery of AID (109). 
Aberrant SHM has also been implicated in oncogenic translocations with the Ig 
		


gene but more importantly in promoting detrimental hypermutations. These 
mutations in non Ig genes, such as those that regulate B cell development, 
regulation, and survival, may promote B cell lymphomagenesis (110-112).  
Studies in transgenic mouse models have elucidated the requirement of AID for 
the development of GC-derived B cell lymphomas, but not lymphomas that 
develop from pre-GC B cells (113). The majority of human B cell lymphomas are 
thought to originate from a transformation event that occurred in the GC 
microenvironment. This is hardly surprising given the mutagenic potential of AID 
in GC B cells where DNA damage in the form of mutations and DSBs is 
encouraged, and cells are highly and rapidly proliferating. TABLE 2 summarizes 
the human B cell lymphomas relevant to this work. 
1.3.2a Burkitt Lymphoma 
  AID is required for the t(8;14) translocation which involves the c-Myc gene 
on chromosome 8 and the IgH locus on chromosome 14 (see Figure 14) (107, 
108). Myc is a transcription factor thought to regulate approximately 15% of 
genes in B cells (114). These include genes responsible for cell cycle regulation, 
apoptosis, and proliferation. Thus, deregulation and constitutive overexpression 
of Myc can lead to compromised cell cycle control, reduction in necessary 
programmed apoptosis, and uncontrolled rapid proliferation promoting genome 
instability and tumorigenesis (115). The t(8;14) translocation is a hallmark of 
human Burkitt Lymphoma (BL). BL is categorized into two subtypes, the endemic 
form which is predominantly found in young children in tropical Africa and the 
sporadic form found throughout the world at a much lower prevalence. Endemic 
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BL is associated with malaria and Epstein-Barr virus (EBV) while the majority of 
the sporadic form is not (116, 117).  
 The c-MYC-IgH translocation in sporadic BL occurs due to breakpoints in 
the S region of the IgH gene, and thus arises due to aberrant CSR (106, 118). 
However, due to breakpoint locations near the V segment of the Ig gene in 
endemic BL, translocations found in this subtype are thought to arise from 
aberrant SHM (119).Characteristic of BL is the expression of surface markers 
normally expressed on GC B cells. In addition, hypermutated V regions are 
detected which indicates the cells have previously undergone SHM. This 
supports the notion that BL originates from GC B cells that have acquired 
transformation during the GC reaction (120). Studies have revealed that BL cells 
are hypermutated at non-Ig genes, are constitutively undergoing acquisition of 
hypermutations, and have undergone antigen selection (121, 122). 
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Figure 14: Schematic of c-MYC-Ig Translocation 
 
 
Figure 14: Schematic of c-Myc-Ig Translocation. The Myc gene (red) is 
located on human chromosome 8 (blue) and the immunoglobulin gene (Ig, 
yellow) is located on chromosome 14 (green). Upon deleterious AID-dependent  
double strand breaks (DSBs) during the GC-reaction and faulty resolution, a 
reciprocal Myc-Ig translocation results where Myc is juxtaposed to Ig (t(8;14) or 
Myc-Ig in the figure). This translocation is a hallmark of Burkitt Lymphoma and 
many lymphomas are found to have translocations between Ig and proto-
oncogenes. Figure created in ChemBioDraw Ultra 14.0 
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TABLE 2: Human B Cell Lymphomas 
 
 
Lymphom
a 
 
(Percent of 
Western 
Lymphomas
) 
 
 
B Cell Type 
Origin 
 
 
Association 
with AID? 
 
Translocations 
& Chromosomal 
Aberrations 
 
 
 
 
References 
 
 
Diffuse 
Large B  
Cell 
(DLBCL) 
 
(30-40%) 
 
 
 
GC B cell 
or 
Post-GC B 
cell 
(plasma) 
 
 
 
Constitutive  
AID expression;  
 
Aberrant CSR and 
SHM 
 
 
MYC-IgH, IgK-
MYC, MYC-IgL, 
Bcl-2-IgH, Bcl-6-
MYC, Bcl-2-IgH; 
 
 ongoing SHM in 
many proto-
oncogenes  
 
 
 
 
(106, 123-
126) 
 
 
Follicular 
Lymphoma 
(FL) 
 
(20%) 
 
 
 
GC B cell 
 
 
Aberrant SHM and 
V(D)J recombination; 
many FLs 
constitutively 
express AID 
 
 
Bcl-2-IgH, 
constitutive SHM 
of the IgH-V 
region & proto-
oncognes in 
many patients 
 
 
 
(127, 128) 
 
 
Burkitt 
Lymphoma 
(BL) 
 
(2%) 
 
 
 
GC B cell 
 
Constitutive AID 
expression,  
constitutive GC 
phenotype and SHM 
 
MYC-IgH  
or  
MYC-IgL 
 
Mutations  
in TP53 and RB2 
 
 
 
 
 
(129-132) 
 
 
 
B- Cell 
Chronic 
Lymphocyt
ic 
Leukemia 
(CLL) 
 
(7%) 
 
 
Pre-GC 
 B cell,  
GC- B cell,  
or 
 Post-GC  
B cell 
 
(ie. naïve, 
GC, or 
memory  
B cells) 
 
 
 
Heterogeneity in AID 
expression- AID is 
expressed at higher 
levels in more 
aggressive forms of 
CLL with an 
unmutated IgH-V 
region; aberrant 
SHM and constitutive 
aberrant CSR 
 
 
 
 
 
Trisomy 12; 
mutations in 
TP53/ATM/ 
NOTCH1/SF3-1; 
deletions in 
17p,13q,11q 
 
 
 
 
 
(124, 132-
135) 
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TABLE 2: Human B Cell Lymphomas (continued) 
TABLE 2: Cell type origin, association with AID, and frequent chromosomal     
 aberrations for relevant human B cell lymphomas are indicated. 
 
 
 
 
 
 
 
 
 
Lymphoma 
 
(Percent of 
Western 
Lymphomas) 
 
 
B Cell Type 
Origin 
 
 
Association 
with AID? 
 
Translocations 
& Chromosomal 
Aberrations 
 
 
 
 
References 
 
Marginal 
Zone 
Lymphoma 
(MZL) 
 
(2%) 
 
 
 
 
Marginal 
zone 
 B cell 
 
 
 
 
No AID expression 
 
 
 
No characteristic 
translocations 
 
Deletion in 7q 
 
 
 
 
(124) 
 
 
Classical 
Hodgkin’s 
Lymphoma 
 
(10%) 
 
 
 
Defective 
GC 
 B cells,  
T cells? 
 
DO NOT 
retain GC 
like traits  
 
 
 
 
AID generally is not 
expressed 
 
 
No characteristic 
translocations 
 
Mutations in 
several tumor 
suppressor genes 
 
 
 
 
(124, 136, 
137) 
 
 
Multiple 
Myeloma 
 
(10%) 
 
 
 
 
Post-GC 
 B cell 
(plasma) 
 
 
AID generally is not 
expressed 
 
Aberrant CSR 
thought to occur 
during transformation 
event 
 
 
 
MMSET-IgH 
FGFR3-IgH 
CCND3-IgH 
CCND31-IgH 
MAF-B-IgH 
 
 
 
 
(138-140) 
	


1.3.2b Diffuse-Large B Cell Lymphoma 
 Diffuse-large B cell lymphoma (DLBCL) is the most prevalent type of non-
Hodgkin’s Lymphoma, accounting for  approximately 30-40% of lymphoma cases 
(141). DLBCL is classified into subgroups based on the phenotype of the 
lymphoma, expression profiles, and the transformation pathways thought to give 
rise to the cancer (142). The germinal center B cell-like (GCB) DLBCL has a 
gene expression profile similar to normal GC B cells and also expresses high 
levels of Bcl-6 which is generally found in centroblasts undergoing the GC 
reaction (143). The activated B cell-like (ABC) DLBCL is thought to arise from 
GC B cells differentiating into plasma B cells due to the down regulation of Bcl-6 
expression in these lymphomas and the upregulation of several plasma cell 
characteristic genes including XBP-1 (142, 144).  
 Like with BL, DLBCLs also have characteristic translocations but these 
may involve the heavy (IgH) or light Ig chains (IgL or IgK). For example, the c-
MYC-IgH [t(8;14)], IgK-MYC [t(2;8)], and MYC-IgL [t(8;22)] translocations are 
diagnostic chromosomal abnormalities in DLBCL patients (145). Translocations 
involving IgH and different oncogenes also are characteristic of DLBCLs, 
including Bcl-6-IgH [t(3;14)] and Bcl-2-IgH [t(18;14)]. Bcl-6 can also be found to 
have other non-Ig gene partners in DLBCL translocations including Myc as in the 
[t(8;30)] (126, 146). Translocations in both ABC-DLBCL and GCB-DLBCL are 
proposed to occur due to illegitimate CSR (147). DLBCL is also known to 
continually undergo aberrant SHM and acquire hypermutations in many non-Ig 
genes throughout the genome due to overexpression of AID (148). 
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1.3.2c Follicular Lymphoma  
 Follicular lymphomas are also thought to arise from B cells that have 
undergone extensive SHM of the V region during the GC reaction, and account 
for ~20% of diagnosed lymphomas (124, 149). Classification of FL is divided into 
four grades based on the type of predominant GC malignant B cells that populate 
the lymphoma. Grade 1 (G1-FL) consists of a majority of cancerous centrocytes, 
G2-FL has both centrocytes and centroblasts, G3A-FL has a minor population of 
centrocytes with a majority of centroblasts, and G3B-FL consist of only malignant 
centroblasts (149). The majority of FLs carry a Bcl-2-IgH translocation, t(14;18), 
which results in the overexpression of Bcl-2 that promotes continued cell survival 
and blocks apoptosis (150, 151). 
 AID continues to be overexpressed in FLs of all grade types and is 
implicated in introducing hypermutations in several proto-oncogenes such as c-
Myc, Pax-5, and Bcl-6 (128, 129). Recent sequencing studies of FL patient 
samples have revealed that AID and aberrant SHM play a role in the evolution 
and multiple recurrence of FL. AID continues to introduce mutations in Ig and 
non-Ig genes shaping both genetic and epigenetic co-evolution of the cancer 
(128, 152).  
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1.3.2d Chronic Lymphocytic Leukemia 
 B-cell chronic lymphocytic leukemia (CLL) is the most prevalent form of 
leukemia but is an extremely heterogeneous cancer which results in variable 
clinical development (153). CLL falls into two essential prognostic groups that 
consist of either having an unmutated IgH V region or a V region that has 
undergone SHM. Patients with a mutated V(D)J segment have a better prognosis 
with a survival median three fold higher than CLL patients with leukemia that did 
not undergo SHM (154, 155).  The B cell type that CLL arises from is debated. 
Pre-GC naïve B cells, post-GC memory B cells, and GC- B cells have all been 
suggested as the origin (124, 156). AID expression in CLL is also quite variable 
ranging from low AID to extremely high AID expression, if expressed at all (156). 
CLL patients can acquire mutations in DNA damage response pathways 
including ATM, as well as tumor suppressor genes such as TP53 (132, 157). 
However IgH translocations are not typically found in CLL. 
1.3.2e Non-GC Derived B Cell Lymphomas 
 The majority of B cell lymphomas do arise from B cells undergoing the GC 
reaction, however, several types of B cell lymphomas thought to originate from 
pre- or post-GC B cells exist. From these two groups, however, more arise from 
post-GC, having at least experienced the GC reaction before transformation, 
than pre-GC B cells. For example, primary effusion lymphoma, multiple 
myeloma, lymphoplasmacytic lymphoma, and hairy-cell leukemia arise from 
plasma B cells or memory B cells (124). 
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 There are also some lymphomas whose origins are still yet not entirely 
understood. Marginal zone lymphoma (MZL) is thought to arise from either pre-
GC or post-GC B cells. There are two groups of MZL characterized by the site of 
infiltration. Nodal-MZL predominantly presents in the lymph nodes while splenic-
MZL infiltrates the spleen and bone marrow. MZL does not carry characteristic 
translocations but approximately 40% of MZLs have chromosomal deletions 
around 7q22-36 (158). Similarly, the origin of classical Hodgkin’s lymphoma 
(cHL) has also been debated, but most likely arises from defective GC B cells 
(124). Hodgkin and Reed-Sternberg cells (HRS) are the cancerous cells in cHL. 
These cells do not retain GC B cell expression profiles or phenotypes and a 
minority of cases are thought to have a T cell origin (159). However non-
beneficial and deleterious mutations in the Ig genes of some cHL patients 
suggest the lymphoma may have derived from the transformation of cells 
destined to undergo apoptosis during the GC reaction (160). cHL cells have 
mutations in several tumor suppressor genes and can also be associated with 
EBV infection, but do not have IgH translocations.  
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1.4 Scope and Significance 
 An overwhelming majority of human B lymphocyte malignancies derive 
from cells that have undergone the GC- reaction and are associated with the 
expression of the mutator enzyme AID. Thus, there is a critical need to elucidate 
the global damage AID inflicts on the genome of normal and transformed cells. 
Studying AID in the context of cancer is important to our understanding of how 
mutations and translocations that promote B-cell lymphomas may arise. This is a 
particularly interesting source of DNA damage because AID’s normal role in 
adaptive immunity requires the deliberate introduction of uracils in the genome 
but its mistargeting, ectopic expression, and aberrant behavior can promote 
genomic instability. Furthermore, unlike most sources of DNA damage that 
promote transformation, for example UV light and ionizing radiation, AID is an 
endogenous enzymatic source of mutations. Recently, other members of the 
APOBEC family have also been implicated in several other non-B cell cancers 
that carry AID/APOBEC mutation “signatures” determined through base 
substitution sequence analysis of the cancer genomes (161, 162). These 
AID/APOBEC mutational signatures were found in cancers of the breast, bladder, 
cervix, and hematopoietic origins.   
 The goal of this research project is to examine the genomic uracil load 
introduced by AID both in normal activated B cells as well as in B cell lymphomas 
and leukemias from patients and cell lines. Since AID can act on non-Ig genes, 
one may predict an increase in the uracil load in the DNA of transformed 
lymphocytes versus normal B cells. Furthermore, most studies that have 
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analyzed the effects of AID on B cell cancers have only examined mutation or 
base substitutions, the indirect consequence of AID activity. Innovatively, the 
direct product of AID deamination, uracil, is studied and quantified here for the 
very first time in several B cell cancer and normal genomes. To achieve this goal, 
a very sensitive biochemical method that I have adapted and optimized was 
implemented in these studies. This uracil quantification assay uses E. coli UNG 
to remove the uracils in the genomes under study, resulting in abasic sites where 
the uracils once were located. Aldehyde-Reactive Probe (ARP) is then used to 
biotinylate these remaining abasic sites and a streptavidin conjugated to a 
fluorophore can then label the biotins. This allows for sensitive detection and 
quantification of uracil sites from the fluorescence signal intensities when a 
standard containing known uracil amounts is processed in parallel. To elucidate 
the difference between AID in cancer and AID in normal activated B-cells 
undergoing antibody maturation, it is important to examine the AID- generated 
uracils in both contexts. 
 This work also methodically and systematically analyzes the direct and 
indirect types of DNA damage and genomic instability that may be promoted by 
AID in B cell lymphoma cell lines. Since AID is an endogenous source of DNA 
damage unlike most mutagens and carcinogens, the types of damages analyzed 
here are those predicted to arise in the cell as a consequence of its attempt to 
repair uracils. For example, the base excision repair machinery of the cell will 
attempt to remove uracils in the genome through excision with proteins such as 
UNG. This will result in an abasic site that can be processed by APE which nicks 
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the DNA (see Figure 9). The study described here examines uracils that AID 
introduces into the genome, abasic sites that uracil excision proteins create, and 
strand breaks that may result from nicks created by APE. Findings that can 
correlate these types and amounts of damage with factors such as AID and uracil 
repair protein expression as well as lymphoma origin will be instrumental in 
understanding B-cell lymphoma development. In addition many forms of 
chemotherapy, such as the use of alkylating agents, aim at creating genomic 
instability. Therefore by methodically testing the types of DNA damage already 
present in B cell lymphomas due to endogenous factors, new combination 
therapy aimed at exacerbating forms of genomic instability detected in this study 
will be important from a clinical aspect. These types of DNA damage are 
important as the initial uracil and its subsequent repair may lead to mutations and 
translocations known to promote lymphoma development.  
1.4.1 Rationale 
 This research provides new prospects for an early detection marker for B 
cell lymphomas. The quantification of uracils in the genomes of patient B cells 
may serve as an indicator of lymphoma development. In addition, knowledge of 
the specific types of DNA damage in lymphomas that accumulate due to AID 
activity can be used to develop new chemotherapeutic strategies that are aimed 
at exploiting and further intensifying these genomic instabilities with the use of 
specific DNA damaging agents. Patient samples from several lymphoma types 
were assessed for these reasons. Finally, an understanding of the extent of 




genomic instability that AID creates may elucidate if AID should be a candidate 
target in treatment strategies. 
1.5 Specific Aims of Research 
AIM 1) The extent of global genomic uracil introduction by AID and the removal 
of uracils by repair enzymes in normal stimulated B cells are examined for the 
first time. Genomic uracils are quantified using a sensitive biochemical uracil 
detection assay to elucidate genome-wide AID activity in adaptive immunity. 
 Although the deamination of cytosine to uracils in single-stranded DNA by 
AID is accepted in the field, there are no previous studies directly quantifying 
uracils and demonstrating AID’s full capacity to introduce uracils in the entire 
genome. The two previous studies of uracils introduced by AID have centered 
only on the Ig gene in murine B cells (163, 164) and used an indirect method for 
quantification, ligation mediated PCR (LM-PCR). Here, a sensitive uracil 
quantification assay is implemented to directly determine the global genomic 
uracil load that AID imposes on murine splenocytes and human tonsil B cell 
genomes. Murine B cells from transgenic mice deficient in uracil repair proteins 
are used to determine which repair enzyme is the primary contributor to the 
removal of genome wide uracils introduced by AID undergoing the GC reaction. 
This study has revealed that in normal B cells a homeostasis, dependent on 
UNG, keeps uracil levels in the genome from accumulating despite AID activity. 
AIM 2) The AID-dependent uracils in B cell lymphomas and uracil removal 
capabilities are examined to determine differences in genomic uracil homeostasis 
in cancer cells where AID is constitutively and ectopically expressed. 
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 The genomic uracils in B cell lymphomas are quantified using a sensitive 
biochemical uracil detection system to determine the full extent of genome-wide 
deamination by AID. This study has identified differences that exist in the total 
genomic uracil load of normal activated B cells with up regulated AID levels 
required for antibody maturation, contrasted with cancerous cells where AID is 
ectopically or constitutively expressed. The genomes of several cancerous 
samples and tissues including patient lymphomas were assessed and compared 
to normal tissues. In addition, the expressions of AID and uracil repair proteins 
such as UNG in lymphomas of GC- or post-GC origins were examined. The 
results suggest that the homeostasis between AID- created uracils and UNG-
mediated excision seen in normal activated B-cells (AIM 1) is disrupted in 
transformed cells that continue to overexpress AID.  
AIM 3) Multiple types of DNA-damage that accumulate as a direct or indirect 
consequence of the constitutive expression of the endogenous mutator enzyme, 
AID, are identified and analyzed in B-cell lymphomas.  
 The mutagenic potential of uracil in U•G mispairs has been exploited as 
an intermediate lesion in the adaptive immunity of mammals. The purposeful 
introduction of uracils in the Ig gene by AID produces mutations and strand 
breaks required for efficient antibody affinity maturation in B-lymphocytes. 
However, when AID is ectopically expressed or aberrantly targets non-Ig genes, 
several downstream pathways that attempt to repair these uracils can in fact lead 
to further genomic instability. Unlike in the Ig-gene where point mutations are 
welcomed for SHM to be effective, and double-strand breaks are necessary for 
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CSR to generate appropriate isotypes, point mutations and strand breaks in other 
genes may be detrimental to the cell or lead to transformation events. If AID is 
constitutively overexpressed in B-cell lymphomas and is able to mutate the 
genome, multiple types of damage may accumulate. This is essential to our 
understanding of lymphoma development and in effective treatment strategies 
because AID is an endogenous enzyme that is introducing the sources of DNA 
damage studied here. To characterize these direct and indirect types of AID-
dependent damage to the genome, several methods were applied to test the 
genomes of B-cell lymphomas for viability, uracil accumulation, AP site 
acquisition, and single- and double-strand breaks. Furthermore, this work led to 
novel findings concerning the genomes of inviable lymphoma cells. 
 
 
 
 
 
 
 
 
 
 
 
 




CHAPTER 2: EXPERIMENTAL PROCEDURES 
Portions of the text in this chapter were reprinted or adapted in compliance 
with the ASM Journals Statement of Authors’ Rights from: 
 
Shalhout S, Haddad D, Sosin A, Holland TC, Al-Katib A, Martin A, Bhagwat AS. 
Genomic uracil homeostasis during normal B cell maturation and loss of this 
balance during B cell cancer development. Molecular and cellular biology. 
2014;34(21):4019-32. doi: 10.1128/MCB.00589-14. 
2.1 Overview of Materials and Methods 
 In order to study several aspects of the role of activation-induced 
deaminase (AID) in normal B cell maturation and lymphomas, several tissues 
were selected for this research including cell lines of germinal center-derived B 
cell lymphoma origin, mouse tissues such as wildtype and transgenic AID-/- mice, 
and several patient samples spanning different types of B cell cancers . All 
protocols involving the use of animals and human tissue materials were subject 
to Institutional Animal Care and Use Committee (IACUC) and Human 
Investigation Committee (HIC)- Institutional Review Board (IRB) approval. To 
accomplish the aims in this research, a sensitive biochemical genomic uracil 
detection method is used in this research and described in detail in this section. 
With this powerful tool, the genomic uracil levels in several tissues were 
examined and compared to AID activity and mRNA levels, and uracil repair 
enzyme activity and mRNA levels (see Figure 15 for an overview). 
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Figure 15: Flow chart of the Tissues Assayed 
 
 
Figure 15: Flow chart of the Tissues Assayed. Messenger RNA, genomic 
DNA, and nuclear and whole cell protein extracts are purified from mouse tissues 
(Top panel), and human lymphoma patient samples, tonsils, normal B 
lymphocytes and cell lines (Bottom panel) and tested as described throughout 
Section 2.1. 
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 To systematically assess the types of DNA-damage that accumulate in 
lymphomas directly or indirectly due to AID, specific types of DNA damage were 
assessed based on the subsequent in vivo processing of uracils introduced by 
AID. Cell lines were assayed for a.) viability in culture, b.) AID expression, c.) 
genomic uracil content, d.) abasic site accumulation, e.) single- strand and  
double- strand DNA breaks. This was carried out utilizing an array of sensitive 
techniques described here. Several molecular biology techniques are employed 
in this research including quantitative real-time PCR, nuclear and whole cell 
activity assays, non-liposomal transfections, transductions, electroporation, and 
short-hairpin knock down of genes to study factors such as AID expression and 
catalytic activity.  
2.1.2 Tissue Samples and Materials for Study 
2.1.2a Mouse Genetic Backgrounds and Tissue Harvest 
 Mice colonies were maintained at the University of Toronto and at Wayne 
State University. Experiments involving animals were performed at the University 
of Toronto and at Wayne State University and were approved by the Ethical 
Committee for Animal Experimentation at the University of Toronto (Toronto, 
Canada) and by the Institutional Animal Care and Use Committee (IACUC) at 
Wayne State University (Detroit, Michigan), respectively. Breeding pairs of AID-/- 
mice were kindly provided by Patricia Gearhart (National Institute on Aging) to 
generate our colony (165).  
 Spleen, liver, and kidney tissues were harvested from twelve to eighteen 
week old C57BL/6 background mice including wildtype mice (WT, control) and 
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the following transgenic mice: UNG-/-, AID-/-, and MSH2-/- mice. Single-cell 
suspensions of splenocytes, hepatocytes, and kidney cells were obtained by 
filtering homogenized tissue samples through a 70-µm nylon-mesh (Corning, 
Falcon). Kidney cells and hepatocytes were directly used for control studies. 
Splenocytes were cultured in RPMI-1640 media (HyClone) supplemented with 
10% fetal bovine serum (HyClone) and 50µM β-mercaptoethanol (Sigma-Aldrich) 
for ex vivo stimulation time course studies (165).  
 AID-/-UNG-/- mice were generated at Wayne State University by crossing 
AID-/- female mice with UNG-/- male mice in a trio breeding format.  
Approximately thirty AID+/-UNG+/- mice (F1) were generated. F1 male mice 
were then bred with F1 female mice (trio breeding) which generated 
approximately 150 offspring (F2). Genotyping of F2 progeny was carried out with 
PCR and 1/25 of F2 mice were detected as AID/-UNG-/-. See TABLE 3 for PCR 
primers used for genotyping (165). Mice with undesired genotypes were donated 
to Division of Laboratory Animal Resources (DLAR) for training purposes as 
needed, or euthanized using approved IACUC protocols. 
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TABLE 3: Primers used to Genotype Mice 
TABLE 3: Primers used to Genotype Mice during generation of AID-/-UNG-/- 
double knockout colony. 
 
 
2.1.2b Murine and Human Cell Lines 
 The murine cell line, J558, is a plasmacytoma cell line that was obtained 
from American Type Culture Collection (ATCC, Rockville, MD).The mouse B cell 
lymphoma cell line, CH12F3.2 and the heterozygous and homozygous AID 
knock-out lines, CH12F3.2 AID+/- and AID-/-, respectively, were kindly provided 
by Kefei Yu (Michigan State University).  
 Several human T- and B- lymphocyte cancer cell lines were obtained for 
these studies. The Epstein-Barr virus (EBV-) negative Burkitt-Lymphoma cell 
lines, Ramos 1 and Ramos 7 were previously referred to as Ramos clone 1-12 
and Ramos clone 7-3 respectively and were kindly provided by A. Martin 
(University of Toronto)(166). Ramos-derived cell lines C.1, A.1, A.2, and A.5 
have also been described (6). The human B cell follicular small cleaved cell 
 
Gene 
 
5’ Primer 
 
3’ Primer 
 
WT AID 
 
 
AID-811 
5’CTGAGATGGAACCCTAACCTCAGCC  
 
AID-G4 
5’CACGATTTTCTACAAATGTATTCCAGC 
disrupted 
AID 
allele 
 
AID-G3 
5’GGGCCAGCTCATTCCTCCACTC 
 
AID-G4 
5’CACGATTTTCTACAAATGTATTCCAGC 
 
WT UNG 
 
 
Up 310 
5’GCCCATCTTGGAAACTCAAA 
 
 
Lower 18 
(5’CCAGTCTGGCTTGGTTACCTTG) 
disrupted 
UNG 
allele 
 
Up 310 
5’GCCCATCTTGGAAACTCAAA 
 
 
Neo1524R 
5’CGTCAAGAAGGCGATAGAA 
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lymphoma line (WSU-FSCCL) (167) and the human diffuse large B cell 
lymphoma line (WSU-DLCL2) (168) were established in the laboratory of Dr. 
Ayad Al-Katib. The human Hodgkin lymphoma cell lines (KM-H2, L-428, L-591) 
and WSU-CLL were obtained from DSMZ (Germany). The Epstein-Barr virus 
positive (EBV +) Burkitt Lymphoma cell lines, Raji and Daudi, the human diffuse 
lymphoma cell lines, RL and Toledo, and acute T cell leukemia and lymphoblast- 
like cell lines (Jurkat and CEM, respectively) were obtained from ATCC. TABLE 4 
summarizes the cell lines used in this work. 
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TABLE 4: Mammalian Cell Lines 
 
Number Name of 
Cell Line 
Lymphoma/Leukemia 
Type 
Source 
 
1 
 
Jurkat 
 
Human Acute 
 T Cell Leukemia 
 
American Type Culture 
Collection (Rockville, MD) 
 
2 
 
CEM 
 
Human Acute T Cell 
Lymphoblastic Leukemia 
 
LeibnizInstitut DSMZ 
(Germany) 
 
3 
 
 
L591 
 
Human Classical 
Hodgkin’s Lymphoma 
 
LeibnizInstitut DSMZ 
(Germany) 
 
4 
 
L428 
 
Human Classical 
Hodgkin’s Lymphoma 
 
LeibnizInstitut DSMZ 
(Germany) 
 
5 
 
KMH2 
 
Human Classical 
Hodgkin’s Lymphoma 
 
LeibnizInstitut DSMZ 
(Germany) 
 
6 
 
ARP1(169) 
 
Human Multiple Myeloma 
 
Wayne State University, 
Detroit, USA 
 
7 
 
FSCCL(167) 
 
Human Follicular, Small 
Cleaved Lymphoma 
 
Dr.AlKatib, Wayne State 
University, Detroit, USA 
 
8 
 
WSU-NHL 
(170) 
 
Human Follicular, Large 
Cell Lymphoma 
 
Dr.AlKatib, Wayne State 
University, Detroit, USA 
 
9 
 
DLCL2(168) 
 
Human Diffuse Large B 
Cell Lymphoma 
 
Dr.AlKatib, Wayne State 
University, Detroit, USA 
 
10 
 
 
Toledo 
 
Human Diffuse Large B 
Cell Lymphoma 
 
American Type Culture 
Collection (Rockville, MD) 
 
11 
 
RL 
 
Human Diffuse Large B 
Cell Lymphoma 
 
American Type Culture 
Collection (Rockville, MD) 
 
12 
 
 
Raji 
 
Human EBV+ Burkitt 
Lymphoma 
 
American Type Culture 
Collection (Rockville, MD) 
 
13 
 
 
Daudi 
 
Human EBV+ Burkitt 
Lymphoma 
 
American Type Culture 
Collection (Rockville, MD) 
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TABLE 4: Mammalian Cell Lines (continued) 
Numbers in red correspond to figure labels in chapter 3 for cell lines indicated. 
TABLE 4 was originally published in the supplementary material for (165) 
Shalhout et al. Genomic uracil homeostasis during normal B cell maturation and 
loss of this balance during B cell cancer development. Molecular and cellular 
biology. 2014;34(21):4019-32. Adapted from the American Society for 
Microbiology.  
 
2.1.2c Isolation of Peripheral B Cells from Healthy Donor Blood 
 Normal B cells were isolated from healthy American Red Cross (ARC) 
donors using peripheral blood collected in apheresis cones and filters. ARC 
donor blood was kindly provided by Dr. Martin Bluth (Associate Director of Detroit 
Medical Center Transfusion Services). Peripheral blood mononuclear cells 
(PBMCs) were first separated from the granulocyte and erythrocyte populations 
using Ficoll-Paque Premium density-gradient media (GE Healthcare, Stem Cell 
Technologies). B cells were initially isolated from the PBMCs using negative 
selection.  A cocktail of biotinylated antibodies specific for surface markers 
present on non-B cells, including natural killer (NK) cells, T lymphocytes, 
dendritic cells, and monocytes was used for labeling the cells (human B cell 
Isolation Kit II, MACS, Miltenyi Biotec). The non-B cells were depleted from the 
Number Name of 
Cell Line 
Lymphoma/Leukemia 
Type 
Source 
 
- 
 
J558 
 
Mouse plasmacytoma 
 
American Type Culture 
Collection (Rockville, MD) 
 
- 
 
CH12F3.2 
 
Mouse B-cell Lymphoma 
 
Kefei Yu (Michigan State 
University) 
 
- 
 
Ramos 
 
Human EBV- Burkitt 
Lymphoma 
 
Alberto Martin 
 (University of Toronto) 
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pool by using magnetically labeled anti-biotin beads. Highly pure B cell 
populations were confirmed with flow cytometry or purified as needed with FACS. 
2.1.2d Cancer Patient Tissues 
 Ethical consideration for the use of patient samples in this research was 
approved following review by the Human Investigation Committee and the 
Institutional Review Board (IRB) at Wayne State University School of Medicine. 
Following informed consent, peripheral blood was collected from lymphoma 
patients during the leukemic phase under the clinical care of Dr. Ayad Al-Katib at 
St. John Hospital Van Elslander Cancer Center Lymphoma Clinic. Some patient 
B cells were purified from thigh lesion biopsies, lymph node biopsies, or pleural 
effusions. No identifying patient markers or information was retained. PBMCs 
were purified from patient whole blood using LymphoPrep density gradient media 
(ProGen Biotechnick GmbH, Germany). The total monocyte cell population was 
depleted from the PBMC suspension cells through adherence to the sterile 
plastic surface of tissue culture flasks. The non-adherent lymphocyte pool of cells 
was collected and B cells isolated through removal of T lymphocytes using 
magnetic bead separation with Dynabeads pan CD2 (Dynal, Life Technologies, 
Grand Island, NY). FACS analysis for each patient sample confirmed the 
recovery of ~95% B cells. These purified B cell populations were utilized in 
expression analysis and genomic uracil quantification studies (165). TABLE 5 
summarizes the patient lymphoma samples, p53 status, and karyotypes.  
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TABLE 5: Lymphoma/Leukemia Patient Summary 
 
 
 
 
Number Age Sex Race Type of 
Lymphoma/
Leukemia 
Cytogenetics/
Karyotype 
P53 
Status 
 
P1 
 
81 
 
F 
 
Caucasian 
 
CLL/SLL 
 
58.5% deleted13q 
 
WT 
 
P2 
 
76 
 
M 
 
Caucasian 
 
CLL/SLL 
84.5% trisomy 12; 
15.5% deletion of 
17p; 11%-loss of 
IgH locus 
 
WT 
 
P3 
 
 
71 
 
F 
 
Caucasian 
 
CLL/SLL 
 
67.5% trisomy 12 
 
WT 
 
P4 
 
64 
 
F 
African- 
American 
 
CLL/SLL 
 
86.5% deleted 13q 
 
WT 
 
P5 
 
62 
 
M 
 
Caucasian 
 
MZL 
 
Normal/46,XY [20] 
 
WT 
 
P6 
 
86 
 
M 
 
Caucasian 
 
MZL 
 
Normal/46, XY [20] 
 
WT 
 
P7 
 
72 
 
 
M 
 
Caucasian 
 
MZL 
 
45% t(2;7) 
(p12;q2122) 
 
WT 
 
P8 
 
61 
 
F 
 
Caucasian 
 
DLBCL 
 
Normal/46, XX [20] 
 
WT 
 
P9 
 
49 
 
F 
 
Caucasian 
 
FL 
 
23%t(14;18) 
(q32; q21.3) 
 
WT 
 
 
P10 
 
 
 
87 
 
 
F 
 
 
Caucasian 
 
 
FL 
55% Complex 
chromosomal 
arrangements; 
t(3,11)(q27;q11); 
t(14;18)(q32;q21.3
) + 
der(18); IgHBCL2 
fusion 
 
 
WT 
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TABLE 5: Lymphoma/Leukemia Patient Summary (continued) 
TABLE 5 was originally published in the supplementary material for (165) 
Shalhout et al. Genomic uracil homeostasis during normal B cell maturation and 
loss of this balance during B cell cancer development. Molecular and cellular 
biology. 2014;34(21):4019-32. Adapted from the American Society for 
Microbiology. 
 
2.1.2e Flow Cytometry for the Isolation of Human naïve mature B Cells from 
Healthy Tonsil Tissues 
 Healthy tonsil tissues were acquired as discarded surgical samples from 
patients with no identifying markers that underwent resection of hypertrophic 
tonsils at Children’s Hospital of Michigan. Tonsils were approved for use in this 
research by the Institutional Review Board of Wayne State University. Tonsils 
were obtained with the assistance of Dr. Kang Chen (Barbara Ann Karmanos 
Cancer Institute and the Perinatology Research Branch, NICHD, NIH).  
 Tonsillar tissue was first filtered through a 70-µm nylon-mesh (Corning, 
Falcon) to yield a single-cell suspension in RPMI-1640 supplemented with 
gentamicin (HyClone). The PBMC fraction was collected using Ficoll-Paque 
Number Age Sex Race Type of 
Lymphoma
/Leukemia 
Cytogenetics/
Karyotype 
P53 
Statu
s 
 
P11 
 
64 
 
F 
 
Caucasian 
 
CLL/SLL 
 
54.5% deleted 13q 
 
WT 
 
 
P12 
 
 
 
69 
 
 
F 
 
 
Caucasian 
 
 
CLL/SLL 
 
 
51% deleted 13q; 
9% deleted 17p 
 
Mt 
 
(K132R
) 
 
P13 
 
 
62 
 
M 
 
Caucasian 
 
CLL/SLL 
 
23.5% deleted 
13q; 26% 3 IgH 
copies 
 
WT 
 
P14 
 
69 
 
F 
 
Caucasian 
 
CLL/SLL 
 
72% deleted 13q 
 
WT 
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Premium density- gradient media (GE Healthcare, Stem Cell Technologies). 
Naïve mature B cells were purified by FACS with IgD-FITC (Southern Biotec 
2032-02), CD19-PECy7 (eBioscience 25-0199-42), CD38-APC (Biolegend 
303510), and CD27-PE (BD 555441) to yield IgD positive, CD19 positive, CD38 
negative, and CD27 negative B lymphocytes. Dead cells were excluded during 
FACS collection by 7AAD (BD 559925) labeling. The purified naïve mature B cell 
population was cultured ex vivo in RPMI-1640 (HyClone) media supplemented 
with 10% FBS (HyClone) and 1% P/S at 37oC and 5%CO2. B cells were activated 
to express AID and undergo CSR by adding 500ng/ml of CD40-L (Peprotech) 
and 50ng/ml of IL-4 (Peprotech) and culturing for seven days. Class switching 
from IgM to IgG1 was confirmed with appropriate antibody labeling and FACS. 
(165). 
2.1.3 Propagation of Cells 
2.1.3a Cell Line Maintenance and Activation 
 J558 was cultured in DMEM (HyClone) supplemented with 10% fetal 
equine serum (FES, HyClone) and 1% P/S. All CH12F3.2 cells were cultured in 
suspension in RPMI-1640 media supplemented with 10% FBS, 50µM β-
mercaptoethanol, and 1% P/S. CH12F3.2 cells were chosen for this study 
because the wildtype cell line expresses AID upon stimulation with a cocktail of 
cytokines and switches from IgM isotype to IgA (1). WT CH12F3.2 AID +/+ and 
the heterozygous and homozygous knock outs, AID +/- and AID -/-, were 
stimulated with CIT. Specifically cells were treated with 1 ug/mL of purified anti-
mouse CD40 (eBiosciences), 10 ng/ml of recombinant mouse IL-4 (R&D 
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systems) and 1 ng/ml of recombinant human TGFβ1 (R&D Systems). Class 
switching to IgA was analyzed and confirmed by flow cytometry. All of the human 
T- and B- cell lines listed in TABLE 4 were cultured in suspension in RPMI-1640 
media supplemented with 10% FBS and 1% P/S.  Cells were incubated at 37oC 
and 5% CO2 in a humidified incubator in T-25cm2 flasks, T-75cm2 flasks, 96-well, 
24-well, 12-well or 6-well sterile plates (Corning). 
2.1.3b Ex vivo Stimulation of Splenic Murine B cells 
 In ex vivo stimulation time course studies, primary splenocytes from WT, 
AID-/-, UNG-/-, and MSH2-/- mice were treated with 25 µg/ml of 
lipopolysaccharide (LPS, E. coli serotype 055:B5; Sigma-Aldrich) to induce 
isotype switching of B cells to IgG3. Switching of primary B cells was confirmed 
with flow cytometry (165).  
2.1.4 RNA Extraction and Quantitative Real-Time PCR (qRT-PCR) 
 Total RNA was extracted from human and murine primary B lymphocytes 
and cell lines using Trizol (Invitrogen) per manufacturer’s protocols and 
instructions. Total RNA was reverse transcribed with anchored oligo-dT primers, 
specifically d(T)23VN where V is A, G, or C and N is A, G, C, or T and the 
ProtoScript M-MuLV First Strand cDNA Synthesis Kit (New England Biolabs). 
cDNA was amplified with HotStart Taq polymerase and RT2 SYBR Green/ROX 
(SA Biosciences, Qiagen) to quantify relative gene expression. qRT-PCR was 
performed with Applied Biosystems 7500 Fast Real Time PCR System and the 
expression levels were determined using the delta Ct method with GAPDH or 
TBP as a reference gene.  
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TABLE 6: Primers for qRT-PCR  
TABLE 6 was originally published in the supplementary material for (165) 
Shalhout et al. Genomic uracil homeostasis during normal B cell maturation and 
loss of this balance during B cell cancer development. Molecular and cellular 
biology. 2014;34(21):4019-32. Adapted from the American Society for 
Microbiology. 
 
2.1.5 Trypan Blue Exclusion Assay  
2.1.5a Percent Viability 
 Cell lines were first stained with Trypan Blue (HyClone) and counted using 
a TC20 Automated Counter (BioRad) to determine the percentage of viable cells. 
Inviable cells were removed from cell lines determined to have <95% viability 
using the Dead Cell Removal Kit (MACS, Miltenyi Biotec) to start each cell line at 
>95% viability at “Day 0.” After three days of incubation, cells were stained with 
Gene 5’ Primer Sequence 3’ Primer Sequence 
Murine 
AID 
 
5’GAAAGTCACGCTGGAG 
 
5’TCTCATGCCGTCCCTT 
Murine 
UNG2 
 
5’GTCTATCCGCCCCCGGAGCA 
 
5’TGGGCGGGGGTGGAACT 
Murine 
SMUG1 
 
5’GAGTGCTGGGATTAAAAGGAT 
 
5’CCAGAATGGGACAAGGATA
G 
Murine 
TDG 
 
5’GTCTGTTCATGTCGGGGCTGA
GTG 
 
5’CTGCAGTTTCTGCACCAGG
ATG 
Murine 
MBD4 
 
5’TGGAGCTGCAGCTGCGCCCC
A 
 
5’CTGCGCTCACTGCTTATCAC
C 
Murine 
GAPDH 
 
5’ACCACAGTCCATGCCAT 
 
5’TCCACCACCCTGTTGCTGTA 
Human 
AID 
 
5’AGAGGCGTGACAGTGCTACA 
 
5’TGTAGCGGAGGAAGAGCAA
T 
Human 
UNG2 
 
5’CCTCCTCAGCTCCAGGATGA 
 
5’TCGCTTCCTGGCGGG 
Human 
SMUG1 
 
SA Biosciences (PPH02717A) 
 
SA Biosciences (PPH02717A) 
Human 
GAPDH 
 
5’TGCATCCTGCACCACCAACT 
 
5’CGCCTGCTTCACCACCTTC 
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Trypan Blue and counted to determine percent cell viability. This was repeated in 
six individual T-25cm2 flasks per cell line tested.  
 
2.1.5b Separation of Dead/Dying Cells from Viable Cells 
 To separately analyze the genomic uracil load in viable and inviable cell 
populations, dead/dying cells were isolated from viable cells using the Apoptotic 
Cell Isolation Kit (Promokine) which utilizes Annexin V magnetic beads that have 
a high-affinity for the phosphatidylserine that dead/dying cells redistribute to the 
outer surface of their plasma membrane. Genomic DNA was prepared from the 
separated populations for uracil quantification (see Figure 16 for schematic). 
 
Figure 16: Isolating Inviable Cells from Viable Cells 
 
Figure 16: Isolating Inviable Cells from Viable Cells. Only dead/dying cells 
with surface phosphatidylserine are labeled with Annexin V conjugated to biotin. 
These cells are then isolated from the pool of cells with streptavidin-conjugated 
magnetic beads.  
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2.1.6 Quantification of Apurinic/Apyrimidinic Sites in DNA  
 Abasic sites, or AP sites, are quantified by adapting a previously 
described biochemical detection method (171). Genomic DNA is extracted from 
cells using the Blood and Cell Culture Kit (Qiagen) or standard DNA extraction 
protocols (172). High molecular weight DNA is then restriction digested with 
HaeIII (New England Biolabs). The endogenous abasic sites in DNA are treated 
with 2 mM aldehyde-reactive probe (ARP; Dojindo Laboratories, see Figure 17 
and 18).  
Figure 17: Aldehyde- Reactive Probe 
 
       Figure 17: Aldehyde- Reactive Probe. The structure of Aldehyde- Reactive    
       Probe (ARP) is depicted above. Figure created in ChemBioDraw Ultra 14.0 
 
 DNA is purified by ethanol precipitation, and filtering through a G-25 
column (GE Healthcare) twice to remove residual reagents. DNA samples are 
then quantified using a NanoDrop ND-2000c (ThermoScientific), and with 
SYBRGold and a BioTek Synergy H1 Hybrid Microplate Reader or a Tecan 
Genios Microplate Reader where concentrations were determined based on a 
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standard calibration plot. Determined amounts of purified DNA samples are 
applied onto a positively charged Immobilon-Ny+ Nylon membrane (Millipore) 
using a vacuum-filtration apparatus (Bio-Rad Bio-Dot Vacuum Apparatus). The 
membrane is pre-equilibrated in double-distilled H2O and 6X SSC (saline-sodium 
citrate buffer) prior to DNA application. 
Figure 18: Reaction of Aldehyde- Reactive Probe with AP Site 

Figure 18: Reaction of Aldehyde- Reactive Probe with AP Site. The reaction 
of an abasic site with aldehyde-reactive probe (ARP) leads to the biotinylation of 
the site. Endogenous abasic sites are labeled this way in the quantification of AP 
sites assay and AP sites generated by the removal of uracils by UNG are 
biotinylated  in this manner in the uracil quantification assay. ChemBioDraw Ultra 14. 
 
 After vacuum spotting the DNA onto the Ny+ membrane, it is incubated in 
StartingBlock buffer (Fisher Scientific) to block non-specific binding, followed by 
incubation in streptavidin-Cy5 (GE Healthcare) in the blocking buffer for one hour 
at room temperature. The membrane is then incubated three times in TBS-T (25 
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mM Tris, 3 mM KCl, 140 mM NaCl, 1% Tween-20) on a rocking platform to wash 
residual fluorophore buffer and scanned using a Typhoon 9210 Phosphorimager 
for Cy5 fluorescence. Cy5 fluorescence signal from samples and standard DNA 
are analyzed with ImageJ software (see Figure 19 for a schematic outline of the 
AP site quantification assay). To convert Cy5 fluorescence intensity signal to 
number of AP sites per million base pair, duplex DNA is used to generate a 
standard plot (see Section 2.1.7b Standard Plot). 
Figure 19: Schematic Outline of AP Site Quantification in Genomic DNA  
 
 
 
Figure 19. Schematic Outline of AP Site Quantification in Genomic DNA. 
Digested DNA is treated with Aldehyde-Reactive Probe (ARP, Dojindo) to 
biotinylate the persistent endogenous abasic sites. The DNA is vacuum 
transferred onto a nylon membrane and incubated with streptavidin-Cy5. The 
membrane is scanned to quantify fluorescence intensity and the signal is 
converted into number of abasic sites using a duplex standard described in 
2.1.7b Standard Plot.  
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2.1.7 Quantification of Genomic Uracils 
2.1.7a Total Uracils in DNA 
 To quantify the total uracils in the genomic DNA of mouse tissues, patient 
samples, and cell lines, a modified ARP-detection method of a previously 
described biochemical procedure is used (173-175). HaeIII (New England 
Biolabs) restriction enzyme digested DNA was treated with 5 mM methoxyamine 
(Mx, Fisher Scientific). This reacts with endogenous AP sites to block their 
labeling in the subsequent ARP treatment step (see Figure 20). To remove 
unbound or excess Mx, DNA is ethanol precipitated and filtered through a G-25 
column (GE Healthcare).  
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Figure 20: Reaction of Methoxyamine with AP Site 
 
 
Figure 20: Reaction of Methoxyamine with AP Site. The reaction of an abasic 
site with methoxyamine (MX) protects the AP site from later reacting with ARP 
treatment and being biotinylated in the uracil quantification assay. All 
endogenous abasic sites are blocked this way in the ensuring ARP labeled 
abasic sites are only those that result from the excision of uracil by UNG. Figure 
created in ChemBioDraw Ultra 14.0 
 
 The DNA is then treated with E. coli UNG (New England Biolabs) and 2 
mM ARP for one hour at 37oC. UNG removes uracils in U:A base pairs, U•G 
mispairs and uracils in single-stranded DNA (see TABLE 1). This allows for total 
removal of genomic uracil and ARP labels the resulting AP sites that remain after 
uracil excision with biotin (see Figure 18). This procedure ensures that detected 
abasic sites are those resulting from uracil excision. The DNA is then extracted 
with phenol: chloroform to remove the UNG enzyme, ethanol precipitated, and 
passed over G-25 columns (GE Healthcare) similar to the AP site detection 
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method. The DNA samples are quantified and spotted onto a Nylon membrane 
and the Cy5 fluorescence detection procedure is identical to that described 
above in 2.1.6 Quantification of Apurinic/Apyrimidinic (AP) Sites in DNA. See 
Figure 21 below for a schematic outline of the total genomic uracil quantification 
assay (165). 
Figure 21. Schematic Outline of the Genomic Uracil Quantification Assay. 
 
 
Figure 21. Schematic Outline of the Genomic Uracil Quantification Assay.  
Digested DNA is treated with methoxyamine to block pre-existing abasic sites. E. 
coli UNG is used to excise uracils and treatment with ARP biotinylates the 
resulting AP sites. The DNA samples are vacuum transferred onto a nylon 
membrane and incubated with Cy5- streptavidin. The membrane is scanned to 
quantify fluorescence intensity and the signal is converted into number of uracils 
using a duplex standard described in 2.1.7b Standard Plot. This figure was 
originally published in the supplementary material for (165) Shalhout et al. 
Genomic uracil homeostasis during normal B cell maturation and loss of this 
balance during B cell cancer development. Molecular and cellular biology. 
2014;34(21):4019-32. Reproduced from the American Society for Microbiology. 
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2.1.7b Standard Plot 
 To quantify the AP sites per million base pair and Uracils (U) per million 
base pair, a standard oligonucleotide duplex containing a single U:G mismatch is 
used in both detection assays. The synthetic 75 base pair duplex DNA (IDT) has 
the following sequence: Top Strand 5’-T37UT37; Bottom Strand 5’-A37GA37. The 
oligos were PAGE purified and the 75mers were annealed (1:2 ratio of top: 
bottom strand) and diluted to a final concentration of 2 x 1011 U per µL. 
  This duplex standard was treated with methoxyamine at 37oC for one 
hour, followed by treatment with an excess of UNG (2 units per 0.5 µg of DNA) 
and 2 mM of ARP for one hours at 37oC. To remove protein and unbound ARP, 
the duplex is phenol:chloroform extracted and ethanol precipitated. It is then 
reconstituted to give a final concentration of 1 x 1010 U per µl. Several dilutions of 
this DNA are vacuum-applied to each Nylon+ membrane, in parallel with genomic 
DNA tested for uracil content or AP site load. This allows for generation of a 
calibration plot of Cy5 fluorescence versus uracil number (or AP site number ) for 
every membrane with spotted test samples. See Figure 22 for a representative 
standard plot. The raw fluorescence numbers are determined with ImageJ and 
are adjusted for background fluorescence signal on each membrane. The 
numbers of uracils or AP sites in the genomic DNAs are determined by 
interpolating their fluorescence intensities using the calibration plot. These 
amounts are normalized for the known amount of DNA loaded for each sample to 
calculate the number of uracils or AP sites per 106 bp. The uracil amount 
calculated is divided by the “control” DNA and allows for a ratio report. The 


 
control for tested murine samples was DNA uracil content level of WT mice 
splenocytes or DNA from unstimulated CH12F3 cells. For human lymphoma cell 
lines or patient tissue samples the control was B lymphocytes purified from the 
blood of American Red Cross donors/volunteers (165). 
 
Figure 22. Representative Standard Plot for Genomic Uracil and AP Site 
Quantification Assay 
 
 
Figure 22. Representative Standard Plot for the Genomic Uracil and AP Site 
Quantification Assays.  Top- A representative fluorescence scan of a Ny+ 
membrane with eight spots containing different amounts of the labeled uracil 
containing duplex DNA ranging from 0 to 35 x 1010 total uracils. Bottom- A 
representative plot of the fluorescence intensity of these spots as a function of 
number of uracils in each DNA duplex spot. The genomic uracils or AP sites in a 
mouse or human DNA sample is calculated by interpolating its fluorescence 
intensity in plots like this generated from standards applied onto each membrane. 
This figure was originally published in the supplementary material for (165) 
Shalhout et al. Genomic uracil homeostasis during normal B cell maturation and 
loss of this balance during B cell cancer development. Molecular and cellular 
biology. 2014;34(21):4019-32. Reproduced from the American Society for 
Microbiology. 
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2.1.7c Uracils in U•G base pairs 
 The uracil quantification assay described above (section 2.1.7a) 
determines the total uracil content of genomic DNA. This is because it uses E. 
coli UNG to excise the uracils and this enzyme removes uracils from single-
stranded DNA and from U:A base pairs in addition to excising uracils from U•G 
and other mispairs. It is important, however, to specifically detect U•G mispairs 
since AID introduces U•G mispairs by deaminating cytosines in C:G base pairs. 
To detect just the uracils in U•G mispairs, the assay was altered to use the 
second uracil-DNA glycosylase in E. coli, Mug. This enzyme is an ortholog of 
mammalian thymine-DNA glycosylase (TDG, see TABLE 1) which selectively 
removes uracils from U•G mispairs and has poor activity on uracils paired with 
adenine (176). Purified MUG enzyme was used in place of UNG in the protocol 
described in section 2.1.7a.  
 The U•G quantification assay protocol requires membrane processing, 
fluorescence acquisition, and interpolation from a standard plot generated by 
spotting dilutions of the duplex oligo exactly as used in the total uracil 
quantification assay. To quantify only U:A bp, DNA was first treated with MUG to 
remove all uracils in U•G bps, then treated with Mx to block these sites from 
being biotinylated. After purification, the DNA is then treated with UNG which 
removes the uracils left in the DNA that are in U:A bps only since previous MUG 
treatment excised all uracils in U•G bps. The AP sites left after UNG removes 
uracils opposite A are then labeled with ARP and the only uracils in U:A base 
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pairs are calculated using a standard, similar to the protocol for AP site and total 
uracil quantification.  
2.1.8 Activity Assays with Whole Cell Extracts (WCE) and Nuclear Extracts (NE) 
2.1.8a Cytosine Deamination Activity Assays 
 Protein preparations from whole cell extracts (WCE) were prepared from 
~1 x 107 cells. Cells were centrifuged and the pellet was resuspended in  buffer I 
[10 mM Tris-HCL (pH 8.0)] and buffer II [10 mM Tris-HCl (pH 8.0), 200 mM KCl, 
2 mM EDTA, 40% (v/v) glycerol, 0.5% NP-40, 2 mM DTT] with the addition of 
protease inhibitor (Halt Protease Inhibitor Cocktail, Thermo Scientific). The cells 
were then incubated at 4ºC for 3 hours with gentle agitation and cellular debris 
was pelleted at 25,000 g at 4ºC. Cell-free protein extract was recovered in the 
supernatant. Nuclear extracts of ~1 x 107 cells were prepared with the NucBuster 
Protein Extraction Kit (Novagen, Millipore) according to the manufacturer’s 
instructions with the addition of three extra washes of each nuclear pellet 
preparation to ensure no cytoplasmic protein contamination occured during 
preparation. Whole cell and nuclear protein concentrations were measured using 
the Bio-Rad protein assay and extracts were snap frozen in liquid nitrogen and 
stored at -80ºC.  
 To assay AID deamination activity in protein preparations, 8 pmols of a 5’ 
6-FAM labeled oligo containing AID’s preferred sequence (WRC, where W=A/T, 
R=purine, 5’-ATTATTACCCATTTATT) was incubated with whole cell or nuclear 
cell extracts for 30 minutes with RNaseA (1 µg), in the following reaction buffer: 
10 mM TrisHCl, pH 7.5, 1 mM EDTA/1 mM DTT, 150mM NaCl. Reactions were 
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incubated at 37°C with a total reaction volume of 20µl and were terminated by 
the addition of 1, 10-phenanthroline (Sigma–Aldrich) to 5 mM. UNG (0.5 units) 
was added to the reactions to excise any uracils introduced by AID deamination 
and incubation was continued at 37 °C for 60 min. Any abasic sites resulting from 
uracil excision were nicked by the addition of  0.1M NaOH and incubation at 95 
°C for 5 min. See section 2.1.8b for reaction product analysis and specific activity 
reports (165).  
2.1.8b Uracil Excision Activity Assays 
 To assay uracil excision activity, 24 pmols of a single-uracil containing 6-
FAM labeled oligomer (5’- ATTATTAUCCATTTATT) is incubated with whole cell 
or nuclear cell extracts for ten minutes at 37ºC in a 20µl total reaction with 1 mM 
EDTA, 1 mM DTT, and 20mM Tris-HCl (pH 8.0) with or without excess Uracil 
DNA-Glycosylase Inhibitor (UGI,New England Biolabs). A single-strand substrate 
is used to avoid detection of uracil excision activity from TDG and MBD4 which 
prefer to remove mispaired uracil from duplex DNA.  Reactions are stopped at 
95ºC for 5 minutes followed by incubation with Proteinase K (Qiagen) for 60 
minutes at 50ºC. Abasic sites are incised using 0.1 mM NaOH treatment at 95ºC 
for five minutes. Reaction products for AID deamination assays (section 2.1.8a) 
and uracil excision assays are analyzed by electrophoresis (15% PAGE, 7M 
Urea, Tris-Borate-EDTA buffer), and a Typhoon 9210 Scanner is used to 
visualize products. Quantification of activity is determined with ImageJ Gel 
Analysis Software and specific activity is reported as pmols of product/min/µg of 
protein (165).  
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2.1.9 Assays for Single-Strand and Double Strand Breaks in DNA 
2.1.9a Comet Assays and Tail moments 
 The comet assay or single-cell gel electrophoresis is utilized in this study 
to detect strand breaks in the genomic DNA of lymphoma cell lines expressing 
AID. This technique requires electrophoresing cells that are embedded in low-
melting agarose and visualizing by fluorescence microscopy. The alkaline comet 
assays were performed using the Comet Assay Silver Kit (Trevigen) according to 
manufacturer’s instructions. Tail moments were quantified using Image J and 
these experiments were carried out by a collaborator (A. Martin, University of 
Toronto). 
2.1.9b Immunofluorescence of γH2AX Foci and Quantification of Foci per     
Nuclei 
 
 Cells were harvested by centrifugation and cell pellets were then 
resuspended in a hypotonic solution and incubated at 37oC for five minutes. 
Approximately ~500 cells were spun onto microscope slides (Fisher) using a 
StatSpin Cytofuge. They were fixed with ethanol:acetic acid, blocked with 3% 
rabbit serum (Hyclone) in PBS to reduce non-specific secondary antibody 
binding, and treated with mouse monoclonal anti-phospho-histone H2A.X 
(Ser139) antibody (Millipore; 05-636). The slides were washed in PBS two times, 
followed by treatment with rabbit anti-mouse IgG antibody conjugated to Cy3 
(Millipore; AP160 C). The slides are washed in PBS and mounted with coverslips 
using VectaShield Mounting Medium with DAPI. Cells were visualized and 
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photographed using a fluorescence microscope (Nikon 80i). The foci per nuclei 
were quantified using ImageJ. Untreated normal B cells and cells treated with 50 
µg/ml zeocin (Invitrogen) served, respectively, as negative and positive controls 
for γH2AX foci analysis. 
2.1.10 Short-hairpin RNA (shRNA) Knockdown of Expression in Lymphoma Cell 
Lines 
 
 AID expression was knocked down in AID expressing lymphoma cell lines 
using shRNA plasmids obtained from SA Biosciences (SureSilencing shRNA 
plasmids for human AICDA for neomycin resistance, KH12741N). Transfection 
grade plasmids were prepared with HiSpeed Plasmid Maxi Kit (Qiagen). Cell 
lines were either electroporated using a Gene Pulser Xcell (BioRad) or 
transfected with shRNA-AID and shRNA-scrambled using FuGeneHD (Promega) 
depending on cell line optimization conditions. Stable clones of shRNA-AID and 
shRNA-scrambled cell lines are selected with G418 (HyClone).  
2.1.11 Expression of Uracil DNA-Glycosylase Inhibitor in Lymphoma Cell       
Lines to reduce Uracil Excision by UNG  
 To inhibit uracil DNA-glycosylase activity, human B cell lymphoma cell 
lines were transfected with pEF (control) and pEF-UGI plasmids by 
electroporation (Gene Pulser Xcell). Cells were diluted in appropriate media and 
plated into 96-well plates. Following 24- 48 hr incubation at 37ºC, stable clones 
were selected with puromycin (Promega). 
2.1.12 Transient Expression of E58A and WT AID in Ramos 1 Cell Line  
  Approximately two million Ramos 1 cells were transfected with 
transfection grade pMSCV-EV (empty vector), pMSCV-E58A, and pMSCV-AID 
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isolated with HiSpeed Plasmid Maxi Kit, (Qiagen) using FuGeneHD (Promega) 
and selected with 2 µg/ml of puromycin (Gibco). The pmax-GFP (Amaxa Lonza) 
plasmid was used to track transfection efficiency with FuGene of the transient 
clones. 
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CHAPTER 3: RESULTS 
Figures and portions of the text in this chapter were reprinted or adapted  
in compliance with the ASM Journals Statement of Authors’ Rights from: 
Shalhout S, Haddad D, Sosin A, Holland TC, Al-Katib A, Martin A, Bhagwat AS. 
Genomic uracil homeostasis during normal B cell maturation and loss of this 
balance during B cell cancer development. Molecular and cellular biology. 
2014;34(21):4019-32. doi: 10.1128/MCB.00589-14. 
3.1 AIM 1- Genomic Uracils in Normal Activated B cells 
 The extent of global genomic uracil introduction by AID and the removal of 
uracils by repair enzymes in normal human and murine stimulated B cells are 
examined for the first time here. Genomic uracils are quantified using a sensitive 
biochemical uracil detection assay to elucidate genome-wide AID activity in 
adaptive immunity. 
 Splenocytes from wildtype C57BL/6 mice were harvested and stimulated 
ex vivo with LPS to closely mimic the activation involved in the normal 
development of B cells during the GC- reaction. Upon activation with LPS, the 
cultured splenocyte population was ≥ 85% B cells shown with flow cytometry.  
For comparison, splenocytes from AID-/- transgenic mice were stimulated in the 
same manner as a negative control for AID-generated uracils. Splenocytes from 
UNG-/- and MSH2-/- transgenic mice which are deficient in two separate repair 
proteins thought to play roles in SHM and CSR were also used in this study to 
determine the effects of these proteins on processing the uracils AID introduces 
during activation of B cells. Finally, splenocytes from AID-/-UNG-/- mice were 
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also tested to demonstrate that the detected uracil content is AID-dependent. 
The total cellular DNA from these cells was isolated and the uracils quantified as 
described in section 2.1.7. DNA from unstimulated splenocytes of each mouse 
background was extracted and also tested for uracil content as ‘non-activated’ B 
cell controls. Liver and kidney tissues were also harvested and single cell 
suspensions from these tissues were studied as the ‘non-B cell’ controls. These 
experiments were designed to determine the amount of genomic uracil that is 
AID-dependent and to elucidate which uracil repair enzyme is primary in global 
genomic uracil removal during the normal GC- reaction of murine B cells.  
3.1.1 Genomic Uracil Quantification of Activated Murine B Cells 
 An image of a Cy5 fluorescence scan of a nylon membrane from one 
representative experiment is shown in Figure 23 where equal amounts of DNA 
from ex vivo stimulated splenocytes under LPS treatment for 3 days were 
spotted. In this and all other uracil quantification studies, different known 
amounts of a duplex containing a U•G mispair were also processed in parallel 
and applied to the membrane to generate a calibration plot as depicted in Figure 
22 (see section 2.1.7b for details). Cy5 fluorescence signals from genomic DNA 
of mice with different genetic backgrounds were converted to uracil amounts 
using the calibration plot, and then uracil amounts in WT splenocytes prior to 
stimulation were used to calculate the fold increases in uracil levels. The 
scanned image strikingly reveals the highest Cy5 fluorescence intensity and 
therefore uracil content in DNA samples from UNG-/- splenocytes stimulated for 
3 days. DNA from UNG-/- unstimulated splenocytes and hepatocytes also 
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contain slightly higher fluorescence intensity compared to other genetic 
backgrounds due to the general lack of UNG available for removal of uracils 
introduced in AID-independent pathways (see Figure 10). The quantified results 
from a typical experiment are presented in Figure 24 A and B. 
Figure 23. Representative Nylon Membrane used in Quantifying Genomic 
Uracils in WT and Transgenic Murine DNA 
 
 
Figure 23. Nylon Membrane used in Quantifying Uracils in Murine DNA. A 
representative mage of a fluorescence scan of a representative nylon membrane  
with equal DNA amounts spotted from triplicate samples of unstimulated murine 
splenocytes (-LPS) and splenocytes stimulated with LPS (+LPS) for 3 days. The 
splenocytes were obtained from WT mice and mice with the indicated genetic 
backgrounds. DNAs were labeled with Cy5 at sites of uracils as described in 
Figure 21. Liver DNAs from the same mice served as negative controls. As 
shown at the top, different amounts of an oligonucleotide duplex containing 
uracils were spotted onto the membrane to create a calibration plot (see Figure 
22).This figure was originally published in (165) Shalhout et al. Genomic uracil 
homeostasis during normal B cell maturation and loss of this balance during B 
cell cancer development. Molecular and cellular biology. 2014;34(21):4019-32. 
Reproduced from the American Society for Microbiology. 
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Figure 24. Genomic Uracils in Murine Splenocytes 
  
 
Figure 24. Genomic Uracils in Murine Splenocytes. (A) Quantification of 
uracils in splenocyte DNA following stimulation with LPS. The fluorescence 
intensities from a membrane similar to the one shown in Figure 23 were used to 
quantify the uracils and were normalized with respect to the uracil amount in WT 
splenocytes prior to LPS stimulation. In these and all other experiments reported 
here, means and standard deviations of the results from triplicate samples are 
reported. (B) Time course of genomic uracil levels in stimulated WT and AID-/- 
splenocytes. Uracils were quantified and the data analyzed as described for A. 
This figure was originally published in (165) Shalhout et al. Genomic uracil 
homeostasis during normal B cell maturation and loss of this balance during B 
cell cancer development. Molecular and cellular biology. 2014;34(21):4019-32. 
Reproduced from the American Society for Microbiology. 
 
 In splenocyte B cell DNA from WT and AID-/- mice, there was no  
detectable increase in the level of uracils during the five day ex vivo stimulation 
time course (Figure 24A and B). This result was readily reproducible (see Figure 
25A and B). This lack of difference in an increase in uracil accumulation between 
WT (ie AID+/+) and AID-/- splenocytes throughout the LPS activation treatment 
was surprising since studies have shown AID can lead to mutations in many non-
Ig genes and causes genome-wide translocations (177, 178). Similarly, there 
was also no increase in the level of genomic uracils when splenocytes from 
A B 
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MSH2-/- mice were activated (see Figure 23, 24A and 25). Thus, despite the role 
of MMR in SHM and CSR (see section 1.2.3d, 1.2.4b and Figure 9) (178-180), 
these results suggest that MMR is not the primary uracil repair pathway involved 
in the removal of global uracils generated by AID across the genome. This result 
is consistent with the well-established role of MMR in correcting replication errors 
and with a previous study that compared relative effects of UNG-dependent 
repair and MMR on SHMs in some AID target genes (178).  
 In contrast, a significant stimulation-dependent increase in uracils was 
observed in UNG-/- splenocytes. Relative to unstimulated UNG-/- splenocytes, 
the genomic uracil levels increased approximately 11-fold in UNG-/- splenocytes 
within the first 3 days following LPS activation. This high uracil accumulation in 
the genomes of UNG-/- splenocytes at day 3 was detected in repeated 
experiments (see Figure 25). In some experiments, an increase of greater than 
11-fold was observed (see Figure 25). The uracil level was then restored back to 
the levels detected in unstimulated cells by the fifth day of the time course (see 
Figure 23 and 24A, red line). The factors likely to contribute to the decrease in 
genomic uracil levels beyond day 3 include a decrease in AID gene expression 
after day 3, possible removal and/or repair of uracils by backup DNA 
glycosylases such as SMUG1, and replicative dilution of incorporated uracils. 
These data are qualitatively consistent with the increased uracil levels in the Ig 
genes of stimulated UNG-/- B cells (163), but the magnitude of the increase I 
detected is much greater than that reported previously. To demonstrate that the 
presence of uracils was due to AID, I quantified genomic uracils in LPS-
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stimulated splenocytes from AID-/-UNG-/- mice. There was no detectable 
increase in uracil levels in AID-/-UNG-/- cells following stimulation, while UNG-/- 
cells stimulated in parallel with the double knock out cells acquired15-fold-higher 
levels of uracils within 3 days (see Figure 26). Together these data suggest that 
splenocyte stimulation with LPS causes a rapid and large increase in genomic 
uracil levels due to AID but that an UNG2-mediated repair pathway eliminates 
the uracils in WT cells. 
3.1.2 Time Course of the levels of AID and UNG2 Gene Expression during B Cell 
Stimulation 
 
 Studies concerning the introduction of uracil by AID into the genome also 
must consider the proteins involved in the removal or repair of those uracils. If 
uracils are readily repaired by several pathways and uracil repair enzymes, AID 
generated uracils may actually be underrepresented or escape detection. To 
elucidate the balance between uracil creation by AID and uracil excision by BER, 
mRNA levels of AID, UNG2, and SMUG1 genes were determined in the LPS 
stimulated mouse splenocytes over a several day time course. 
  In activated splenocytes from WT, UNG-/-, and MSH2-/- genetic 
backgrounds, AID gene expression levels increased ~20-fold relative to 
unstimulated splenocytes. mRNA levels were normalized to the house-keeping 
gene, GAPDH (glyceraldehyde 3-phosphate dehydrogenase) which was used as 
an internal control in these studies (see section 2.1.4 for qRT-PCR details). 
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Figure 25. Genomic Uracil Results are Reproducible 
 
Figure 25. Genomic Uracil Results are Reproducible. (A) Independent 
experiment showing a Ny+ membrane used for uracil quantification from a 
different study with different mice samples than that shown in Figure 23 for 
murine splenocyte and liver DNAs. Each labeling reaction contains equal 
amounts of DNA spotted onto the membrane (350 ng) and the reactions were 
done in triplicates. Stimulation with LPS was carried for three days. (B) 
Quantification of uracils from part A. The numbers are normalized with respect to 
the number for unstimulated WT cells (set to 1.0). Mean and standard deviation 
are shown. Sp- splenocytes; Hp- hepatocytes. This figure was originally 
A 
B 
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published in the supplementary material in (165). Reproduced from the American 
Society for Microbiology. 
 
Figure 26. Genomic Uracil Levels in AID-/-UNG-/- Splenocytes 
 
Figure 26. Genomic Uracil Levels in AID-/-UNG-/- B cells. Relative genomic 
uracil levels in LPS-stimulated splenocytes from UNG-/- and AID-/-UNG-/- double 
knock out mice normalized to uracil levels in unstimulated WT splenocytes.This 
figure was originally published in (165). Reproduced from the American Society 
for Microbiology. 
 
 This sharp increase in AID gene expression upon stimulation occurred 
during the first 3 days following stimulation and was reduced thereafter, never 
quite reaching pre-stimulation levels by the end of the five day time course 
(Figure 27). As expected, no AID mRNA was detected in the samples prepared 
from the AID-/- cells (see Figure 27 B, blue line). In stimulated splenocytes from 
WT mice, the rise and fall of UNG2 gene expression paralleled AID gene 
expression. UNG2 and AID both increased approximately 20-fold compared to 
levels in unstimulated cells during the first 3 days and declined thereafter (Figure 
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27A). The increases in UNG2 mRNA levels following stimulation of WT 
splenocytes were correlated with increases in single-strand-specific uracil 
excision activities in both nuclear extracts (Figure 29) and whole-cell extracts 
(Figure 30). UGI, a specific inhibitor of the UNG enzymes, almost completely 
eliminated the uracil excision activity (Figure 29 and 30). Such upregulation of 
UNG2 following B cell stimulation has been noted before (181). 
 
 
Figure 27. Gene Expression in Stimulated Murine Splenocytes 
 
Figure 27. Gene Expression in Stimulated Murine Splenocytes. The mRNA 
levels of AID (blue), UNG2 (red), and SMUG1 (green) genes relative to the 
GAPDH expression level (set at 100) are shown. The gene expression levels 
were determined prior to and subsequent to LPS stimulation of splenocytes from 
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WT (A), AID-/- (B), UNG-/- (C), and MSH2-/- (D) mice. This figure was originally 
published in (165). Reproduced from the American Society for Microbiology. 
 
3.1.3 Cytosine Deamination during B Cell Stimulation 
 
 Nuclear protein extracts and whole cell protein extracts were prepared 
from WT and UNG-/- cells to test the cytosine deamination activity using a 
fluorescently labeled single-stranded DNA substrate containing a cytosine within 
the AID hotspot sequence motif, WRC (see section 2.1.8a for assay details). The 
cytosine deamination activities were similar in the two types of cells and peaked 
at day 3 following stimulation with LPS (Figure 28). Thus, both AID mRNA levels 
and DNA-cytosine deamination activities follow the same general pattern of 
increase and decline in the two genetic backgrounds. The increase in cytosine 
deamination was seen using whole cell extracts as well as nuclear extracts. 
However, of significance here is the increase in deamination activity upon 
stimulation detected specifically in the nucleus because only nuclear AID can 
lead to uracil accumulation in genomic DNA. 
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Figure 28. Nuclear and Whole Cell Cytosine Deamination Activity  
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Figure 28. Nuclear and Whole Cell Cytosine Deamination Activity. A time 
course of DNA-cytosine deamination activity in nuclear extracts (A) and whole 
cell extracts (B) prepared from LPS-stimulated splenocytes from WT (green) and 
UNG-/- (blue) mice. Specific activity was calculated as picomoles of DNA 
substrate converted to product per microgram of protein in the extract per minute. 
Part A of this figure was originally published in (165). Reproduced from the 
American Society for Microbiology. 
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Figure 29. Nuclear Uracil Excision Activity 
 
 
Figure 29. Nuclear Uracil Excision Activity. A fluorescently labeled DNA 
oligomer containing uracil was incubated with nuclear extract from WT (A) or 
AID-/- (B) LPS-stimulated splenocytes, and the specific activity of uracil excision 
was determined. The activity was determined in the presence (+Ugi)  or  absence 
(-Ugi) of the UNG enzyme inhibitor UGI.. This figure was originally published in 
(165). Reproduced from the American Society for Microbiology. 
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Figure 30. Whole Cell- Uracil Excision Activity 
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Figure 30. Whole Cell- Uracil Excision Activity. A fluorescently labeled DNA 
oligomer containing uracil was incubated with whole cell extract prepared from 
WT (A) or AID-/- (B) LPS-stimulated splenocytes, and the specific activity of 
uracil excision was determined. The activity was determined in the presence 
(+Ugi) or absence (-Ugi) of the UNG enzyme inhibitor UGI.  
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3.1.4 The Repair of Genomic Uracils during Normal B Cell Stimulation 
 
 Although UNG2 gene expression increased in AID-/- splenocytes following 
LPS stimulation, the magnitude of the increase was smaller than in WT mice 
(Figure 27A and B). In contrast to this result, a previous study using 
transcriptome sequencing (RNA-Seq) found UNG expression to be about the 
same in stimulated B cells from WT and AID-/- mice (182). To resolve this issue, 
I determined the uracil excision activity in nuclear extracts (Figure 29) and whole 
cell extracts (Figure 30) from AID-/- cells and found that it also peaked at day 3 
post stimulation but that its magnitude was smaller than the peak activity seen in 
WT cells (compare Figure 29A and B and Figure 30A and B). This activity was 
eliminated when UGI was added to the reaction mixture, showing that it was 
UNG  specific. As predicted,  no  expression  of  UNG2  gene  was  detected  In  
UNG-/-splenocytes (Figure 27C). In MSH2-/- splenocytes, UNG2 gene 
expression followed the same pattern as in WT cells (Figure 27D).  
 In contrast to UNG2 gene expression, there was no increase in the 
expression of SMUG1 gene in any of the genetic backgrounds tested (Figure 
27A through D). Similarly, splenocyte stimulation did not lead to large increases 
in expression of other uracil-specific DNA glycosylases (TDG and MBD4) 
following stimulation of WT splenocytes (see Figure 31). Thus, despite recent 
reports that SMUG1 contributes more to uracil excision than UNG2 in mice (181) 
and that SMUG1 contributes to CSR and SHM in mice (183), these results  show 
that UNG2 is the only uracil specific DNA glycosylase whose expression is 
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upregulated in response to B cell stimulation. Thus, it must be responsible for the 
repair of an overwhelming majority of uracils created by AID in stimulated WT B 
lymphocytes. In other words, B cells undergoing maturation ex vivo display 
homeostasis in genomic uracil levels. 
Figure 31. Gene Expression Levels of Uracil Repair Proteins 
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Figure 31. Gene Expression Levels of Uracil Repair Proteins. Expression 
levels of AID (green), TDG (black), MBD4 (red), UNG2 (blue), and SMUG1 
(purple) in LPS stimulated WT splenocytes were determined. qRT-PCR results 
are shown above for unstimulated WT cells (day 0) and cells 3, 4, and 5 days 
post-stimulation with LPS. The expression levels of the genes are relative to 
GAPDH expression level and re-normalized to the gene expression levels at Day 
0 (set to 1.0).This figure was originally published in (165). Reproduced from the 
American Society for Microbiology 
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3.1.5 Genomic Uracil Levels in Activated human Naïve B Lymphocytes  
 To extend these observations to human B cells, I purified mature naive B 
cells from tonsil tissues obtained from two human donors and stimulated the B 
cells ex vivo with anti-CD40 antibody and IL-4 to mimic the GC-reaction. The AID 
expression and genomic uracil levels were determined in the cultured B cells 
over a 7 day time course. AID expression increased substantially in both sets of 
samples after 4 days of stimulation, but the magnitudes of the increase were 
different in the two samples (Figure 32A). Regardless, the genomic uracil level 
changed little over the 7 days in either sample (Figure 32B). This shows that, like 
the WT murine splenocytes, normal human B cells maintain their genomic uracil 
levels following stimulation despite an increase in AID expression. A similar 
increase in the expression of UNG2 also increased upon stimulation (Figure 
32C).  
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Figure 32. Gene Expression Levels and Uracils in Human B Cells
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Figure 32. Gene Expression Levels and Uracils in Human B cells. Naive 
mature B cells were isolated from tonsils from two independent donors and cells 
were stimulated with anti- CD40 antibody and IL-4 for 7 days. AID (A) and UNG2 
(C) expressions were normalized to GAPDH expression (with the day 0 level set 
to 1.0). (B) The quantification of the genomic uracil levels in the ex vivo-
stimulated tonsillar B cells relative to uracil levels in DNA from unstimulated cells 
are shown (with the day 0 level set to 1.0). Panel A and B of this figure were 
originally published in (165). Reproduced from the American Society for 
Microbiology. 
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3.2 AIM 2- Genomic Uracils in Cancerous B cells 
 The AID-dependent global uracil levels in B cell lymphoma genomes and 
the uracil removal capabilities are examined. The genomic uracil homeostasis 
found in normal activated B cells is lost in cancer cells where AID is constitutively 
and ectopically expressed. 
3.2.1 Uracil accumulation in murine B cell Lymphoma lines despite high UNG2 
activity and expression 
 
 To determine whether the lack of uracil accumulation in the genome of 
activated WT B cells was also true in germinal center-derived cancer cell lines, I 
studied uracil accumulation in the genome of the CH12F3 cell line since it is a 
murine B cell lymphoma-derived line that expresses AID upon stimulation with 
CIT and switches from the IgM isotype to IgA (see section 1.1.1 for more details) 
(1). The levels of genomic uracils and the expression of AID, UNG2, and SMUG1 
genes in this cell line following its stimulation were determined and compared 
with the pattern seen in WT and UNG-/- murine splenocytes.  
 Three days post stimulation, CH12F3 cells accumulated uracils in their 
genome to a level about fourteen times the unstimulated level (Figure 33A). As 
was observed in LPS-stimulated UNG-/- splenocytes (Figure 24A), the uracil 
content decreased after day 3, returning to the unstimulated level by day 10. 
 To directly compare the uracil amounts in the genomes of these two types 
of murine cells, equal amounts of DNA from primary WT and UNG-/- splenocytes 
and from CH12F3 cells were labeled at uracil sites and the samples were spotted 
on nylon membranes for quantification. A fluorescence scan of the membrane 
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
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shows roughly equal intensities for DNA from UNG-/- splenocytes and CH12F3 
cells after 3 days of stimulation (Figure 33B).  
Figure 33. Uracil Levels in CH12F3 Stimulated Cells
 
 
Figure 33. Uracil Levels in CH12F3 Stimulated Cells. (A) Time course of the 
change in genomic uracil levels in CH12F3 DNA with or without CIT stimulation. 
(B)Fluorescence scan of a nylon membrane on which equal amounts of DNAs 
labeled at uracil sites from unstimulated WT and UNG-/- mouse splenocytes and 
unstimulated CH12F3 cells were spotted. DNAs from splenocytes stimulated with 
LPS or CH12F3 cells stimulated with CIT for 3 days were labeled for uracil 
quantification in parallel and also spotted onto the membrane. The panels in this 
figure were originally published in (165). Reproduced from the American Society 
for Microbiology. 
B 
CH12F3 
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 Quantification confirmed that the two sets of DNAs had similar levels of 
uracil content and that these amounts were much higher than those seen with 
the unstimulated CH12F3 cells and both unstimulated and stimulated WT primary 
splenocytes (see Figure 34). Therefore, stimulated CH12F3 cells behave like 
stimulated UNG-/- cells in terms of genomic uracil accumulation.  
 Both the AID and UNG2 expression profiles of CH12F3 cells were similar 
to those of stimulated WT splenocytes (compare Figure 34 B, C and Figure 27A). 
The kinetics of AID gene expression in CH12F3 cells was paralleled by nuclear 
DNA-cytosine deamination activity (Figure 35), and the same pattern was seen 
with UNG2 gene expression and nuclear uracil excision activity (Figure 36A and 
B). Furthermore, the peak specific activities of cytosine deamination and uracil 
excision in the nuclear extracts of CH12F3 cells were comparable to those in WT 
splenocytes (compare Figure 28A with Figure 35 and Figure 29 with Figure 36B). 
SMUG1 gene expression did not change detectably following CH12F3 
stimulation, similar to ex vivo stimulated primary B cells (see Figure 37 and 27A). 
Thus, CH12F3 cells accumulated uracils in their genome following their 
stimulation despite the fact that their AID and UNG2 gene expression and 
nuclear enzymatic activity profiles were similar qualitatively and quantitatively to 
those in WT splenocytes. 
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Figure 34. Uracil Levels in Primary B Cells versus CH12F3 Cells 
 
 
 
 
 
Figure 34. Uracil Levels in Primary B Cells versus CH12F3 Cells.
(A) Genomic uracil levels in splenocyte DNA and CH12F3 DNA before and at 
day 3 following LPS stimulation were determined. Levels are normalized to the 
uracil content in WT cells prior to stimulation. (B) Direct comparison of AID 
expression relative to GAPDH in WT splenocytes and CH12F3 cells. (C) Direct 
comparison of UNG2 expression relative to GAPDH in WT splenocytes and 
CH12F3 cells. qRT-PCR was done in parallel using the same primers. The 
panels in this figure were originally published in the supplementary material of 
(165). Reproduced from the American Society for Microbiology. 
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Figure 35. AID expression and Nuclear Cytosine Deamination Activity in 
CH12F3 Cells 
 
 
Figure 35. AID expression and Nuclear Cytosine Deamination Activity in 
CH12F3 Cells.Time course of change in AID gene expression and cytosine 
deamination activity in nuclear extracts prepared from CIT-stimulated 
CH12F3 cells.This figure was originally published in (165). Reproduced from the 
American Society for Microbiology. 
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Figure 36. UNG2 expression and Uracil Excision Activity in CH12F3 Cells 
 
  
 
 
 
 
 
Figure 36. UNG2 expression and Uracil Excision Activity in CH12F3 Cells.
(A) UNG2 expression in CH12F3 cells relative to GAPDH gene expression (set at 
100). (B) Time course of change in uracil excision activity in nuclear extracts 
prepared from stimulated CH12F3 cells in the presence or absence of UGI. This 
figure was originally published in (165). Reproduced from the American Society 
for Microbiology. 
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Figure 37. SMUG1 expression in CH12F3 Cells 
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Figure 37. SMUG1 expression in CH12F3 Cells. SMUG1 expression in 
stimulated (+CIT) and unstimulated (-CIT) CH12F3 cells relative to GAPDH gene 
expression (set at 100). 
 
 To directly compare gene expression in CH12F3 cells with gene 
expression in murine splenocytes, qRT- PCR was performedon equal amounts 
of cDNA from the two cell types using the same set of primers and internal 
controls. The results showed that in both of the cell types, AID and UNG2 gene 
expression peaked at day 3 and the peak mRNA levels of both the genes were 
about 20% to 30% lower in CH12F3 cells than in the splenocytes (see Figure 34 
B and C). To compare the UNG2 excision activities of the two cell types, I 
performed parallel uracil excision assays with nuclear extracts from WT 
splenocytes and CH12F3 cells prior to stimulation and at 3 days following 
stimulation and electrophoresed the products on the same gel. The gel showed 
that CH12F3 cells had uracil excision activity comparable to that of WT 
splenocytes (Figure 38). Thus, stimulated CH12F3 cells show AID gene 
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expression, deamination activity, UNG2 gene expression, and uracil excision 
activity similar to those seen in stimulated WT splenocytes but accumulate 
uracils like stimulated UNG-/- splenocytes. 
Figure 38. Nuclear Uracil Excision Activity is similar in Stimulated Primary 
and CH12F3 B cells 
 
 
 
Figure 38. Nuclear Uracil Excision Activity is similar in Stimulated Primary 
and CH12F3 B cells. Uracil excision activity in nuclear extracts from stimulated 
WT splenocytes (+LPS) and CH12F3 cells (+CIT). DNA containing uracil was 
treated with the indicated amount of extract, and the products were 
electrophoresed on a denaturing gel following strand cleavage. “Day 0” indicates 
unstimulated cells, and “Day 3” indicates cells stimulated for 3 days.This figure 
was originally published in (165). Reproduced from the American Society for 
Microbiology. 
 
 The uracil accumulation detected in CH12F3 cells only occurs upon CIT 
stimulation, and therefore induction of AID. However, some GC-derived cancers 
constitutively and ectopically express AID (see TABLE 2). The J558 cell line, a 
murine plasmacytoma cell line that constitutively expresses AID (184), was 
chosen to investigate whether its genome contains uracils like the stimulated 
CH12F3 cell genome. Both AID and UNG2 genes were expressed in J558 at 
levels between unstimulated and stimulated WT splenocytes (Figure 39A). The 
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J558 genome contained ~25-fold as much uracil as unstimulated UNG-/- 
splenocytes, and this amount was less than what was found in the stimulated 
UNG-/- splenocytes tested in parallel experiments (Figure 39B). Thus, this 
murine cell line derived from a B cell myeloma expresses UNG2, but still exhibits 
higher uracil content than B cells that have not undergone stimulation mimicking 
maturation in germinal centers. These murine cancer cell line results suggest that 
the loss of balance between uracil creation and elimination may be a common 
feature of B cell cancers expressing AID. 
Figure 39. J558 Gene Expression and Uracil Levels 
 
Figure 39. J558 Gene Expression and Uracil Levels. (A) Gene expression 
levels in J558 and splenocytes. Expression Levels of AID, UNG2 and SMUG1 
were determined for stimulated and unstimulated WT and AID-/- splenocytes and 
J558. The expression levels of the 3 genes are relative to GAPDH expression 
level (set at 100).(B) Quantification of uracils in the genome of UNG-/- mice  prior 
to stimulation (-LPS) and at day 3 following stimulation (+LPS) compared to uracil 
levels in the genome of the mouse plasmacytoma cell line, J558. Data from 
triplicate samples are shown with error bars representing standard deviation. 
(*** P< 0.0001) 
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3.2.1Uracil accumulation in human B cell Lymphoma lines  
 
 To determine whether the correlation observed between high AID levels 
and high genomic uracil occurrence, despite high UNG2 expression, in murine B 
cell cancers also extends to human B cell cancers, I studied 13 cell lines created 
from human hematopoietic malignancies (see TABLE 4). Specifically, seven of 
the cell lines tested are B cell lymphomas of GC origin, including two BL lines, 
two  FL lines, and three DLBCL lines. In addition, a MM line and two T 
lymphoma/leukemia lines were also studied. Finally, three cHL lines were also 
studied. Although many cHL tumors show some evidence of GC development 
(185), they usually do not express AID at high levels (137).   PBMCs from healthy 
blood of human volunteers were used as negative controls serving as non-AID 
expressing B cells. 
 The GC-derived cell lines (ie. BL, FL, and DLBCL) had significantly higher 
levels of AID expression and genomic uracils when compared to the non-GC 
derived or characteristic cell lines. The BL, DLBCL, and FL cell lines express AID 
at levels ranging from about 4 to 8% relative to GAPDH gene expression (Figure 
40, top panel, closed bars). This is in contrast to the non-GC-derived lines, cHL 
lines, and normal cells which had less than 1% AID gene expression (Figure 40 
top panel, open bars). The nuclear DNA-cytosine deamination activities were 
consistent with the AID mRNA levels in the cell lines (see Figure 40 and 41).  
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Figure 40. AID Expression and Uracils in Human Lymphoma Cell Lines 
 
Figure 40. AID Expression and Uracils in Human Lymphoma Cell Lines.AID 
gene expression and genomic uracil levels in 13 human lymphoma-derived lines 
and circulating human B cells. (Top) The AID expression levels are shown 
relative to the GAPDH gene expression level (set at 100). Numbers on the x-axis 
refer to the specific cell line detailed in TABLE 4. The asterisk indicates no 
detectable expression. (Bottom) Genomic uracil levels relative to those in 
circulating human B lymphocytes (set at 1.0).This figure was originally published 
in (165). Reproduced from the American Society for Microbiology. 
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Figure 41. Human Lymphoma Nuclear Cytosine Deamination Activity 
 
Figure 41. Human Lymphoma Nuclear Cytosine Deamination Activity. 
Nuclear cytosine deamination activity for some of the cell lines. The asterisks 
indicate that no deamination activity was detected under these conditions. This 
figure was originally published in (165). Reproduced from the American Society 
for Microbiology. 
  
 The genomic uracil levels in the high-AID expressing cell lines, BL, FL, 
and DLBCL, were quite high compared to the MM, cHL and T-cell lines. 
Specifically, the GC-characteristic lines had genomic uracils 80- to 120- fold the 
level found in normal PBMCs (Figure 40, bottom panel, closed bars). In contrast, 
some of the low-AID B cell lines contained genomic uracils at levels that were 
only two to five times those seen with normal PBMCs while the tested T cell lines 
had uracil levels comparable to normal B cells (Figure 40, bottom panel, open 
bars). When the genomic uracil levels in these cell lines were plotted against 
their AID gene expression levels, the high-AID and low-AID lines clearly 
separated into distinct groups (see Figure 42A). Stimulated tonsillar cells had 
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somewhat higher uracil levels than peripheral B cells, and the low-AID lines had 
uracil levels comparable to those found in the tonsillar cells (see Figure 42B). 
Figure 42. Uracil versus AID in Human B Lymphoma Cell Lines 
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Figure 42. Uracil versus AID in Human B Lymphoma Cell Lines. (A) The 
genomic uracil levels in the human lymphoma cell lines are plotted against AID 
mRNA expression levels. (B)The genomic uracil levels in naïve B cells purified 
from tonsil donor 1 without stimulation and 4 days post ex vivo stimulation with 
CD-40L and IL-4 are shown relative to levels in circulating normal B cell DNA 
isolated from peripheral healthy donor blood. Normal B-cells are set to 1.0. 
(mean ± S.D. from triplicates) The dashed lines indicate the upper and lower 
values of the relative uracil levels for the low-AID group from Figure 5A to 
indicate the genomic uracil level range found among the tested T-cell, classical 
Hodgkins Lymphoma, and Multiple Myeloma cell lines.This figure was originally 
published in the supplementary material of (165). Reproduced from the American 
Society for Microbiology. 
 
 Since it is an inherent property of cancers to have genomic instability 
(186), it was possible that the B cell cancer cell lines were not stable with regard 
to genomic uracil content. In particular, it is possible that continual cytosine 
deamination by AID increases the uracil content of high- AID cell lines with time. 
However, when the Raji cell line was followed over many passages, no 
consistent increase or decrease in the uracil content was observed (Figure 43). 
A 
B 
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Thus, the B cell lymphoma- derived high-AID cell line displayed stable uracil 
content, albeit at much higher levels than normal B cells. 
Figure 43. Stable Uracil Levels in Raji 
 
Figure 43. Stable Uracil Levels in Raji. Uracil levels in the Raji cell genome 
over several passages. The uracil level in Raji cells at passage 1 (P1) was set at 
100. This figure was originally published in (165). Reproduced from the American 
Society for Microbiology. 
 
3.2.2 Uracil excision activity in human B cell cancers overexpressing AID 
 
 One possible cause of elevated uracil levels in high-AID cell lines and 
tumor samples is a reduction in uracil excision activity. To test this possibility, I 
performed qRT-PCR measurements of UNG2 and SMUG1 mRNA in the human 
cell lines in addition to uracil excision activity assays on several cell lines (Figure 
44). The mRNA quantification studies showed that high-AID cell lines also 
expressed UNG2 and SMUG1 genes at moderately higher levels than PBMCs 
(Figure 44A). While the higher UNG2 expression seen in these cells was similar 
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to the increased UNG2 expression seen in stimulated WT murine splenocytes 
and CH12F3 cells, the increase in SMUG1 expression was not observed in 
murine cells (Figure 27 and 37). 
Figure 44. UNG2 expression and Uracil Excision Activity in human 
lymphoma cell lines 
 
 
 
Figure 44. UNG2 expression and Uracil Excision Activity in human 
lymphoma cell lines.A)The UNG2 and SMUG1 expression levels in the same 
human cell lines as described for Figure 40 relative to the GAPDH expression 
level.(B) Uracil excision activity in nuclear extracts prepared from a subset of the 
human lymphoma cell lines in the absence UGI (left) or in its presence (right). 
This figure was originally published in (165). Reproduced from the American 
Society for Microbiology. 
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 I performed the uracil excision activity assay for two low- AID lines and 
seven high-AID lines in the presence or absence of UGI. The high-AID nuclear 
extracts showed 50% to 100% more uracil excision activity than the low-AID 
extracts tested (Figure 44B, left panel). This activity was abolished when UGI 
was included in the reactions (Figure 44B, right panel), confirming that it was due 
to UNG2. Furthermore, the specific activities of the nuclear extracts from high-
AID cell lines were comparable to the peak activity seen in nuclear extracts from 
murine splenocytes (compare Fig. 29 and 44B). These results show that the 
UNG2 gene expression is not defective in high-AID human B cell cancer cell 
lines and that they contain nuclear uracil excision activity comparable to that 
seen with stimulated WT murine splenocytes. Despite this activity, they contain 
very high levels of uracils in their genome. 
3.2.3 Genomic uracil levels change with AID  
 To determine whether increases or decreases in the expression of AID in 
human cell lines causes commensurate changes in genomic uracil levels, I used 
previously generated variants of the Ramos cell line that express AID at different 
levels (166).These included cell lines Ramos 7 (high AID gene expression) and 
Ramos 1 (low AID gene expression) (166) and lines created through transfection 
of a plasmid expressing AID into Ramos 1 (Ramos A.1, A.2, and A.5) or the 
empty vector (Ramos C.1) (43).  
 The expression of AID was much higher in Ramos 7 than in Ramos 1 cells 
and was higher in Ramos A.2 and A.5 cells than in Ramos C.1 cells (Figure 45, 
top panels) as expected. Correspondingly, the genomic uracil level in Ramos 7 
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cells was higher than in Ramos 1 cells, and there was a similar relationship 
between genomic uracil levels in the Ramos A.2 and A.5 lines and in Ramos C.1 
cells (Figure 45, bottom panels). Thus, Ramos-derived cell lines with higher AID 
expression show a pattern of higher genomic uracil levels as seen in the high-
AID group of cell lines (Figure 40). To test whether the catalytic activity of AID 
was required for the increase in genomic uracils, I transfected a catalytically 
inactive version of AID (E58A) into Ramos 1 cells. Both WT AID and E58A AID 
gene transfection increased AID mRNA levels (Figure 46, left panel), but only the 
catalytically active version increased genomic uracil levels (Figure 46).  
Figure 45. AID and Uracils in BL Ramos Derived Lines 
 
 
Figure 45. AID and Uracils in BL Ramos Derived Lines. (Top panel) AID 
expression in Ramos 1 and Ramos 7 lines and in the Ramos 1-derived lines 
transfected with empty vector (Ramos C.1) or with an AID expression plasmid 
(Ramos A.1, A.2, and A.5). (Bottom panel) Genomic uracil levels in the same cell 
lines. In both cases, the numbers were normalized relative to uracils in normal 
circulating human B cells (set to 1.0). The asterisks indicate undetectable 
expression. This figure was originally published in (165). Reproduced from the 
American Society for Microbiology. 
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Figure 46. WT and E58A AID 
 
 
Figure 46. WT and E58A AID. (Left panel) Relative expression levels of WT AID 
and the AID E58A mutant following transient transfection of Ramos 1 cells. The 
AID level in Ramos 1 transfected with an empty vector was set to 1.0. (Right 
panel) Genomic uracil levels in the same transient-transfection experiment 
relative to uracils in the empty vector control (set to 1.0). This figure was 
originally published in (165). Reproduced from the American Society for 
Microbiology. 
 
 Interestingly, UNG2 gene expression was highest in the three BL cell lines 
expressing AID at very high levels, Ramos 7, Ramos A.2, and Ramos A.5 (see 
Figure 47A). This suggests that when Ramos cells were transfected with AID-
expressing plasmids, endogenous UNG2 gene expression levels may have 
lagged behind increasing AID expression levels, allowing the genomic uracil 
levels to rise, but that the uracil excision ability eventually caught up with uracil 
generation by AID stabilizing the genomic uracil content at a higher level than 
before. 
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Figure 47. Expression of Uracil Repair Enzymes in Human Cell Lines 
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Figure 47. Expression of Uracil Repair Enzymes in Human Cell Lines. (A) 
UNG2 and SMUG1 gene expression in Ramos-derived cell lines. mRNA levels 
for Ramos 1 and Ramos 7 lines, and the Ramos 1-derived lines transfected with 
empty vector (Ramos C.1) or with an AID expression plasmid (Ramos A.1, A.2 
and A.5) are shown. The levels are normalized to GAPDH levels set at 100. (B) 
UNG2 expression levels in AID-knockdown cell lines. UNG2 mRNA levels are 
presented as percentage of mean values for the negative controls expressing 
scrambled-shRNA. This figure was originally published in the supplementary 
material of (165). Reproduced from the American Society for Microbiology. 
 
 To study the effects of reducing AID gene expression on genomic uracil 
levels, I transformed human cell lines expressing AID at high levels with plasmids 
expressing AID-specific shRNA. The levels of success of the knockdown (KD) 
differed among the cell lines, but AID gene expression in all the lines was 
reduced by 75% or greater compared to the expression seen with a control line 
expressing scrambled shRNA (Figure 48, top  panel). All the AID KD lines had 
substantially reduced genomic uracil levels compared to their scrambled shRNA 
counterparts, but the degrees of reduction were different for different cell lines 
(Figure 48, bottom panel). The variability in the reduction in genomic uracil levels 
among different KD lines may have been due to differences in genetic 
backgrounds between the cell lines and the fact that they represent three 
A B 
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different B cell lymphomas. For example, SMUG1 levels or dUTP pools may be 
different in different cell lines and this may have secondary effects on genomic 
uracil levels. It should be noted that UNG2 gene expression changed in the same 
direction as the change in AID gene expression in these cell lines (see Fig.47B).             
Figure 48. Knock-down of AID in Human B cell Lines 
 
Figure 48. Knock-down of Human B cell Lines. Effects of AID knockdown on 
human lymphoma cell lines. The AID mRNA levels and genomic uracil levels are 
presented as the percentages of the mean values for the line expressing 
scrambled shRNA. (Top panel) AID expression in cell line expressing AID-
specific shRNA. (Bottom panel) Genomic uracil levels in the same cell lines. This 
figure was originally published in (165). Reproduced from the American Society 
for Microbiology. 
 
 
 



 
3.2.4 Genomic Uracils in AID-expressing patient B cell lymphomas 
 I tested tumor samples from six pretreatment lymphoma patients (referred 
to as patients P5 through P10) (see TABLE 5) and determined the levels of AID 
gene expression and genomic uracil in the B lymphomas. AID gene expression 
was higher in FL and DLBCL patient tumors than in the three MZL patient 
samples (Figure 49A, open bars). MZL tumors are thought to originate from post-
GC marginal- zone B cells and thus, the low AID gene expression in these 
tumors is consistent with their origin. The patients from whom the tumor samples 
were obtained were unrelated individuals, and their cancers were at different 
stages and had different cytogenetic markers (see TABLE 5). Consequently, it is 
not surprising that the patients within each group (patients with DLBCL or FL and 
patients with MZL) showed considerable variation in AID gene expression levels 
(Figure 49A). Regardless, the genomic uracil levels were much higher in FL and 
DLBCL tumors than in normal B cells and the MZL tumors. The uracil levels in FL 
and DLBCL tumors were comparable to those seen in most FL and DLBCL cell 
lines (compare Figure 40A and 49A, closed bars). In contrast, the MZL tumors 
had amounts of uracils in their DNA that were only slightly higher than those 
seen with normal B cells (Figure 49A, closed bars). 
 In addition, I also tested tumor samples from eight patients with CLL 
(patients P1 through P4 and P11 through P14, see TABLE 5). CLL tumors are 
known to be heterogeneous with respect to AID gene expression and I also 
detected a range of AID gene expression in the CLL patient samples. In contrast, 
there was little tumor-to-tumor variation in UNG2 and SMUG1 levels (Figure 
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49C). However, there was a strong correlation between AID gene expression and 
genomic uracil levels (Figure 49B). The correlation observed between elevated 
AID gene expression and accumulation of uracils in the genomes of human cell 
lines holds also for the patient tumor samples. 
Figure 49. Gene Expression and Genomic Uracil Levels in Patient Tumor 
Samples 
  
 
Figure 49. Gene Expression and Genomic Uracil Levels in Patient Tumor 
Samples. The patients and the numbering are described in TABLE 5. (A) AID 
expression levels and uracil levels in lymphoma patient samples. Genomic uracil 
levels are indicated relative to those in normal circulating human B lymphocytes 
(set at 1.0). (B) AID expression levels and uracil levels in CLL patient samples. 
(C) UNG2 and SMUG1 gene expression in the same CLL patient B cells. 
Expression data are normalized to GAPDH expression set at 100. This figure 
was originally published in (165). Reproduced from the American Society for 
Microbiology. 
 
3.3 AIM 3- AID- dependent DNA Damage in B cell Lymphomas 
 As discussed above, AID is essential for normal B cell development and 
required for SHM and CSR (see section 1.1). The point mutations and strand 
breaks introduced during these processes result from the actions of a number of 
enzymes in addition to AID, including UNG, APE, MMR proteins, and TLS 
polymerases (see section 1.2) (187, 188). Although the regulation of the AID 
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gene and its transcript ensure that it is principally expressed in GC B cells, 
results from Aim 1 of this work suggest that murine splenocytes (see section 3.1) 
stimulated to overexpress AID introduce uracils at a large number of genes, not 
necessarily restricted to the Ig genes. These uracils are subsequently eliminated 
by an UNG-dependent excision repair process (165). Additionally, several 
studies have shown that AID can target many non-Ig genes introducing 
mutations including oncogenes such as MYC, PAX-5, PIM1, and BCL2 in B 
lymphocytes (178, 189).  
 Results from Aim 2 reveal that B cell lymphomas that overexpress AID 
maintain a high level of uracil in their genomes (165). To test whether the 
downstream processing of the initial uracil lesions leads to an accumulation of 
other types of DNA damage, I subjected human lymphoma cell lines that 
overexpress AID and have high levels of genomic uracils to abasic site 
quantification, single- and double strand break analysis, and cell viability studies. 
Many of these cell lines contain high levels of these lesions in an AID-and Ung- 
dependent manner. Furthermore, results suggest this accumulated DNA damage 
may compromise genomic stability. 
3.3.1 Expression of AID and accumulation of genomic uracils in cancer cell lines 
 I confirmed AID expression levels relative to TBP in six of the GC-derived 
lymphoma cell lines used in Aim 2 (see Figure 50A). AID mRNA levels in FL, 
DLBCL, and BL lines were 13 to 22 fold higher relative to the endogenous TBP 
mRNA levels in each sample.  This is in distinction to AID levels in the T cell 
lymphoma and cHL cell lines where AID mRNA levels were below TBP 
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expression. AID mRNA was not detected in B cells isolated from non-cancerous 
donor peripheral blood. To specifically confirm deamination activity in the 
nucleus, I prepared nuclear extracts from these cell lines to assay nuclear 
cytosine deamination activities using a single-stranded fluorescently labeled DNA 
oligo with a cytosine in the sequence context preferred by AID. When products 
were electrophoresed following uracil excision of any deaminated cytosines and 
abasic site cleavage with alkaline and heat treatment, nuclear cell deamination 
activity was easily detected in the FL, DLBCL, and BL lines (Figure 50B, and 
Figure 41). No deamination product was observed in the T-cell extracts while one 
of the two tested cHL lines showed limited but detectable product. Thus, both the 
nuclear DNA-cytosine deamination activities and the AID mRNA expression 
levels are highest in the GC-characteristic B cell lymphomas confirming results in 
Aim 2. 
3.3.2 Accumulation of AP sites in cancer cell lines 
 The genomes of lymphomas expressing elevated AID levels contain an 
excess of uracils in their genomes (see Figure 40), but these cells also express 
SMUG1 and UNG2 genes at normal or higher than normal levels (see Figure 
44A). This implies that SMUG1 and UNG2 enzymes will attempt to excise this 
surplus of uracils establishing many abasic sites. Any subsequent processing of 
abasic sites by AP endonucleases can create strand breaks. To study this, I 
utilized a variety of biochemical assays.  
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Figure 50: AID expression and Cytosine Activity in Human Cell Lines 
 
Figure 50: AID expression and Cytosine Activity in Human Cell Lines. (A) 
The AID expression levels are shown relative to TBP. Asterisk indicates no 
detectable expression in normal B-cells isolated from PBMCs of healthy donors. 
(B) An oligonucleotide DNA containing cytosine in AID’s preferred sequence 
context was treated with equal amounts of nuclear extracts from each cell line 
and the products were electrophoresed on a denaturing gel following treatment 
with E. coli UDG to excise any deaminated cytosines and nicking with alkaline 
and heat treatment. The percent product is shown below the denaturing gel.  
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 I quantified the AP sites in the DNAs by using a previously established 
method that also utilizes ARP (see section 2.1.6) (190). Briefly, endogenous 
abasic sites are biotinylated with ARP, which allows for quantification of the AP 
sites. It should be noted that this assay detects all aldehydic adducts in DNA 
including intact AP sites, AP sites cleaved by AP endonuclease or other enzymes 
and the formamido forms of a number of oxidation and alkylation-induced 
damage (191). As there is no indication that the amount of oxidation and 
alkylation damage to DNA changes when AID is abundant, I refer to the number 
of all sites labelled during this assay as abasic or AP sites for textual 
convenience. There are approximately 0.5 AP sites per million base pair in 
normal B cell DNA (donor age range 20 to 30 years) and T cell and cHL lines 
were found to contain slightly higher amounts at statistically insignificant levels. 
Strikingly, 10 to 20 AP sites per million base pair were detected in the high AID-
expressing cell lines- FL, DLBCL, and BL. This is almost 20 to 40 fold higher than 
normal B cell AP site levels (Figure 51). In these high-AID expressing cell lines, 
there are one-fifth to one-tenth as many persistent AP sites as uracils in the 
DNA.  
 To study the effects of reducing AID expression on accumulated AP sites, 
I analyzed the level of AP sites in stable cell lines established by knocking down 
the expression of the AID gene with AID-specific shRNA versus scrambled-
control shRNA in select high AID expressing lines (see Figure 48). This reduction 
in AID also reduced the detectable AP sites (Figure 52). A significant reduction in 
the number of AP sites in the scrambled shRNA group when compared to the 
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AID- knock down (KD) lines is observed. All of the high-AID expressing cell lines 
had a higher number of AP sites than normal B cells, and in each case, the 
number of AP sites did not exceed the number of genomic uracils in the DNA.  
Figure 51: AP Sites in Human Cell Lines 
 
Figure 51: AP Sites in Human Cell Lines. Abasic sites are quantified using a 
biochemical detection method where DNAs are treated with aldehyde reactive 
probe to label endogenous abasic sites, followed by labeling with Cy5-
streptavidin. (see Figure 19 for assay details). AP sites from cell line DNA were 
quantified in parallel with DNA from healthy peripheral blood B cells (normal B-
cells, age 20-30). 
 
3.3.3 Accumulation of Single- and Double Strand Breaks 
 To examine if single- and double strand breaks in the genome change in 
relation to AID levels, the Ramos 1 (low-AID) and Ramos 7 (high-AID) (see 
Figure 45 top left for AID expression) cell populations were subjected to the 
alkaline comet assay and a wide distribution of tail lengths was detected with tails 
visually longer for Ramos 7 than Ramos 1 (A. Martin, D. Haddad, University of 
Toronto) (Figure 53A and B). This is reflected in the quantified tail moments of 
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these two cell lines, where Ramos 7 had about twice as high a tail moment as 
Ramos 1.The tail moments of Ramos 1 cells increased to the level of Ramos 7 
when the former cells were subjected to an ionizing radiation dose above 4 Gray 
(Figure 53B). Therefore, the higher levels of AID in Ramos 7 are correlated with 
a higher number of genomic single- and double strand breaks. 
Figure 52: AP Sites in Human AID knock-down Cell Lines 
 
Figure 52: AP Sites in Human AID knock-down Cell Lines. AP sites were 
quantified in DNAs from stable cell lines prepared by transfecting the parental 
cell lines in Figure 51 with either a control scrambled shRNA (scrm) or an AID-
specific shRNA (KD) to knock down expression.  
 
 Following removal of dead and dying cells from the cultures, the low- and 
high- AID expressing cell lines were stained with anti-γH2AX antibody to detect 
the marker for DNA DSBs. The FL, DLBCL, and BL cell lines frequently showed 
nuclei with several foci (Figure 54A, right panels). In contrast, the T-cell and cHL 
lines had fewer nuclei positive for staining (Figure 54B, left panels). The number 
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of foci per nuclei was counted using the Image J software and this confirmed the 
conclusions drawn from visual observations (Figure 54B). 
Figure 53: AID dependent Strand Breaks 
 
 
Figure 53: AID dependent Strand Breaks. (A) Representative false color 
alkaline comet assay images of Ramos 1 and Ramos 7 cells. Cells were 
synchronized in G1 with mimosine. (B) Tail moments of ~100 cells of Ramos 1 
and Ramos 7 are plotted. Ramos 1 cells were irradiated at indicated grays shown 
below plot. Bars indicate median tail moment values. *** p< 0.05 (P value 0.009). 
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Figure 54: γH2AX and Double Strand Breaks  
 
 
Figure 54: γH2AX and Double Strand Breaks. (A) (Left) Representative 
images of low-AID expressing cells and (Right) high-AID expressing lines stained 
for γH2AX (yellow). Cells were stained with DAPI (blue) and images merged. (B) 
Quantification of γH2AX foci per nuclei in lymphoma cell lines. Foci per nuclei 
were quantified for ~100 cells for each sample using ImageJ Software. Lines 
indicate median foci per nuclei values. **** P<0.0001 comparing low AID 
expressing foci and high-AID expressing foci.  
 
Fo
ci
 
pe
r 
N
u
cl
ei
0
2
4
6
8
10
20
40
60
80
100
1 2 3 4 5 6 7 8 9 10
T-Cell cHL
FL
DLBCL
Burkitt
R
aj
i
D
au
d
i
****
A 
B 



 
 The fairly wide variation in the number of foci and the existence of cells 
without any foci in every cell line population suggests that a single-strand break 
generated during the repair of AID-introduced uracils is converted to double 
strand breaks in only a fraction of the cells- possibly the cells actively replicating 
their DNA. Regardless, there is a clear correlation between high AID expressing 
cell lines and the accumulation of DSBs in their DNA. 
 To determine if the presence of DSBs is directly dependent on the 
presence of AID, AID-KD cell lines and the corresponding shRNA-control lines 
were also stained for γH2AX. A significant decrease in the mean number of foci 
per nuclei was observed when comparing the quantification of γH2AX foci 
staining of ~100 FL-KD cells with the FL-scrambled control cell line (Figure 55). 
This same pattern of decrease was seen in the KD versus shRNA-control cell 
lines established with DLBCL and BL lines (Figure 54) supporting AID’s role in 
the promotion of the genome wide detected DSBs. 
3.3.4 Overall Effect on Cell Viability 
 I initially noticed that the high-AID expressing cell lines grew at slower 
rates than the low-AID expressing cell lines. Further, the accumulation of uracils, 
AP sites, and strand breaks in the genomes of high-AID expressing cell lines 
promote genomic instability and may lead to increased cell death. To determine if 
this is the case, dead cells were removed and cultures with ~100% viability were 
grown for three days, stained with Trypan Blue, and counted using a TC20 
Automated Cell Counter (Bio-Rad). The results show a correlation between AID 
expression and higher cell death. Cultures of cell lines with the highest AID 
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expression levels, FL, DLBCL, and BL, had the highest percentage of inviable 
cells (up to 30%), while those with the lowest AID levels, T-cell and cHL lines, 
remained close to 90% viable (Figure 56A) with a lower percentage of dead cells. 
Furthermore, by simply knocking down AID in the high AID-expressing cell lines, 
cell viability was restored to >85% viability when directly compared to the 
corresponding shRNA-control lines which maintain poorer viability grown under 
the exact conditions (Figure 56B).  
Figure 55. DSBs Reduced in AID Knock-downs 
 
Figure 55. DSBs Reduced in AID Knock-downs. Quantification of γH2AX foci 
per nuclei in extablished cell lines where AID expression was knocked down (KD) 
with shRNA targeting AID versus scrambled control shRNA (scrm).**** P<0.0001 
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Figure 56. Viability of Human B Cell Lymphomas 
 
Figure 56. Viability of Human B Cell Lymphomas. (A) Percent viability in 
human B cell lymphomas. (B) Restoration of viability in extablished cell lines 
where AID expression was knocked down (KD) with shRNA targeting AID versus 
scrambled control shRNA (scrm).**** P<0.0001 
 
 With an increase in genomic instability and cell death culminating from 
AID-introduced uracils, I decided to determine the levels of uracils in inviable 
cells to see if dead/dying cells accumulated larger amounts of uracils or if this 
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population of cells has lower uracil levels from attempted repairs that 
overwhelmed the cells and lead to apoptosis. Viable cells were isolated from 
inviable cells in the FL, DLBCL, and BL cell lines using Annexin-V magnetic 
beads and uracils were quantified. Surprisingly, in every case there were more 
uracils in the genomes of inviable cells than viable cells (Figure 57). In most of 
the cell lines, a two-fold or higher level of uracil was detected in the inviable 
population as compared to the viable population.  
Figure 57. Uracils in Viable and Inviable Human B Cell Lymphomas 
 
Figure 57. Uracils in Viable and Inviable Human B Cell Lymphomas. Relative 
uracil levels in inviable cells of human B cell lines with the uracil levels in viable 
cells set to 1.0 in each line tested. 
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3.3.5 DNA Damage due to Attempted Repair by UNG 
 UNG enzyme is one of the principal defense mechanisms mammalian 
cells have against accumulation of uracils in the genome, playing a major role in 
the excision of this base (see section 1.2.3b) (192). To determine whether 
accumulation of damage is effected specifically by the UNG glycosylase, I 
expressed the UNG enzyme inhibitor UGI in the same FL, DLBCL, and BL high 
AID-expressing cell lines. Although successful UGI expressing lines were created 
from these tumor lines, individual clones derived from each line showed 
considerable variability in growth. Some clones grew poorly or died off 
suggesting that inhibition of UNG2 enzyme in these cells beyond a certain level 
may be toxic. Regardless, I was able to establish cell lines with less than 50% 
uracil excision activity compared to corresponding cells transfected with the 
empty vector (EV) control from each of the five high AID-expressing lymphoma 
cell lines (Figure 58A, Top panel). Expression of UGI caused the genomic uracil 
levels to go up by ~30% (Figure 58A, Bottom panel). This confirms that UNG2 is 
one of the principal enzymes that helps eliminate the uracils created by AID in B 
cell lymphomas. 
 The removal of uracils by UNG enzyme results in abasic sites (see Figure 
12). It reasons that if AP site accumulation is due primarily to the attempted 
repair of the AID-introduced uracils, then a reduction in this repair may reduce 
AP site accumulation as well. With inhibition of UNG in these UGI-expressing 
cells, a 2 fold to 4-fold reduction in the number of AP sites was observed when 
comparing the cell lines expressing empty vector to their UGI-expressing 
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counterparts (Figure 59). A similar reduction was observed in the γH2AX foci in 
the nuclei of those cells expressing UGI (Figure 60). This significant decrease in 
accumulated DSBs further implicates the attempted repair of uracils by UNG as 
one pathway that leads to genomic instability in these high- AID expressing cell 
lines. 
Figure 58. Uracils in Human B Cell Lymphomas Expressing UGI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58. Uracils in Human B Cell Lymphomas Expressing UGI. (Top panel) 
Uracil Excision activity assays were performed on the UGI expressing cell lines 
and the corresponding cells lines expressing an empty vector (EV). The specific 
activity of uracil excision in the EV-expressing cells was set at 100%.(Bottom 
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panel) The genomic uracils were quantified in the UGI- expressing cell lines and 
the EV-expressing (set at 100%). 
 
Figure 59. AP Sites in Human B Cell Lymphomas Expressing UGI 
 
Figure 59. AP Sites in Human B Cell Lymphomas Expressing UGI. AP sites 
were quantified in the FL, DLBCL, and Burkitt lymphoma cell lines transfected 
with an empty vector (EV) or a plasmid expressing UGI (UGI). 
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Figure 60. DSBs in Human B Cell Lymphomas Expressing UGI 
 
 
Figure 60. DSBs in Human B Cell Lymphomas Expressing UGI. γH2AX foci 
per nuclei were quantified with Image J for cell lines expressing UGI or the empty 
vector (EV) for ~50 cells per line. **** P<0.0001 
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Figure 61. Percent Viability Compromised further in Human B Cell 
Lymphomas Expressing UGI 
 
 
Figure 61. Percent Viability Compromised further in Human B Cell 
Lymphomas Expressing UGI. Percent viability of six independent cultures each 
was determined for FL, DLBCL, and BL cell lines expressing UGI or the empty 
vector (EV) using the Trypan Blue Exclusion assay. Lines indicate median 
percent viability.  
 
 Finally, with a reduction in uracils, AP sites, and DSBs, I expected the 
UGI-expressing cell lines would restore cell viability due to reduction in overall 
genomic instability. However, when the cells were subjected to the Trypan Blue 
exclusion assay, an even higher percent of cell death approaching nearly ~50% 
(Figure 61) in the UGI-expressing FL, DLBCL, and BL established lines was 
observed. This reduction in cell viability may be an indicator that the reduction of 
repair of the uracils by partially inhibiting UNG leads to toxic and overwhelming 
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mutations throughout the genome that may actually result in poor propagation of 
the cell lines.  
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CHAPTER 4: DISCUSSION 
Figures and portions of the text in this chapter were reprinted or adapted in 
compliance with the ASM Journals Statement of Authors’ Rights from: 
 
Shalhout S, Haddad D, Sosin A, Holland TC, Al-Katib A, Martin A, Bhagwat AS. 
Genomic uracil homeostasis during normal B cell maturation and loss of this 
balance during B cell cancer development. Molecular and cellular biology. 
2014;34(21):4019-32. doi: 10.1128/MCB.00589-14. 
4.1 Loss of Genomic Uracil Homeostasis in AID-expressing B Cell 
Lymphomas 
 
 AID’s role in the adaptive immune system is an exceptional biological 
process since it is the only identified mechanism in which cells intentionally 
require damage to genomic DNA sequences to achieve benefit to the organism. 
Previous reports established the hypothesis that AID is a cytosine deaminase 
based on genetic studies as well as in vitro biochemistry. Cells are equipped with 
several repair pathways that excise uracils, but in the process, may lead to base 
substitutions and strand breaks. However, prior to this work, the specific 
relationship between AID- generated uracils and their subsequent excision by 
UNG or MMR had not been examined in normal B cell development or B cell 
lymphomagenesis. This research examined the interplay and resulted in novel 
findings and conclusions. 
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4.1.1 First Demonstration of Uracil Accumulation in Splenocyte Genomes 
 This study revealed that UNG-/- splenocytes acquire a substantial level of 
uracils upon AID activation through stimulation and that this rise in uracils was 
not seen in AID-/- splenocytes (Figure 26). Although an accumulation in genomic 
uracils was not entirely surprising since AID has been shown to be a DNA-
cytosine deaminase in vitro (11-14), this study is the first to directly demonstrate 
AID-dependent uracil accumulation in the genomes of B lymphocytes undergoing 
activation. In addition, transient-transfection studies revealed that the catalytic 
activity of AID was required for its ability to increase genomic uracil levels (Figure 
46). While another contributing factor to genomic uracil accumulation may be due 
to high transcription levels in stimulated B cells possibly leading to increased 
dUTP incorporation during replication, as was recently shown to be the case in 
yeast cells (193), the research described here clearly demonstrates that the 
deamination of cytosines in DNA by AID leads to the increase in genomic uracils 
of stimulated B lymphocytes (165). 
 The large increase in uracil accumulation suggests that the majority of the 
cytosines deaminated by AID are outside the Ig genes. In LPS treated UNG-/- 
splenocytes, the genomic uracil content increased from 11 to 60 fold (Figure 24A, 
26, 25B and 34A). There was variation in the level of the genomic uracil increase 
seen in B cells from independent mice but an increase of at least 11 fold or 
higher was always detected and reproducible. The uracil quantification assay 
was always done by assaying DNA samples in triplicate, processing all the 
compared samples in an experiment in parallel, applying them to the same Ny+ 
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membrane, and always alongside the uracil standard (Figure 23, 25A, and 33B). 
However, uracil content is reported here as fold changes and not uracils per 
million base pair because this assay uses a convenient synthesized duplex oligo 
as the uracil standard which does not represent true physiological DNA. In 
addition, previous studies using various uracil detection techniques have 
reported anywhere from 200 (194) to 15,000 (195) uracils in the unstimulated 
PBMC genome. Therefore, there may be around several thousand uracils per 
haploid genome in stimulated B cells deficient in UNG. Recently, only one uracil 
per kilobase was reported in the Ig genes (25) following B cell stimulation. Thus 
the majority of the uracils introduced by AID in stimulated UNG-/- B cell are in 
non-Ig genes. 
4.1.2 Homeostasis in Uracil Creation and Excision Upon B Cell Stimulation 
 In ex vivo stimulated WT mouse B cells and human naïve mature B cells, 
uracils created by AID were efficiently eliminated with no detectable uracil 
increase resulting. Surprisingly, the level of genomic uracils in LPS activated 
mouse WT B cells was comparable to the level detected in AID-/- B cells (Figure 
24B). I also confirmed that there was no detectable uracil increase in murine WT 
B cells upon IL-4 and LPS ex vivo stimulation which results in a different isotype 
switching than LPS alone (Figure 62). This lack in increased global genomic 
uracil accumulation in stimulated WT splenocytes suggests that UNG2 removes 
the uracils introduced by AID quickly and efficiently. Thus, a genomic uracil 
homeostasis exists in B lymphocytes undergoing the GC-reaction and antibody 
affinity maturation (Figure 63, upper panel).  
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4.1.3 B Cell Lymphomas Accumulate Uracil despite UNG2 Activity and 
Expression 
 
  The high uracil accumulation detected in murine and human B cell 
cancers overexpressing AID suggests a lack of efficiency in the ability of UNG2 
to remove uracils introduced by AID. Initially, to explain the increase in uracil in 
lymphoma genomes, I simply reasoned that (1) either AID was expressed at 
much higher levels in lymphomas than activated WT B cells, or that (2) UNG2 
was expressed at far lower levels in lymphomas. Experiments showed neither of 
these to be the case when studying the proteins at the expression or activity 
level. While an increase in the level of genomic uracils was only detected in 
stimulated primary B cells deficient in UNG, lymphomas accumulated high uracil 
levels but expressed UNG2 at normal or higher than normal levels and had 
robust detectable nuclear uracil excision activity. Specifically, nuclear excision 
activities in LPS-activated WT B cells and lymphoma cell lines overexpressing 
AID were similar (see Figure 29A, 36B, and 44B). The same was true for AID 
expression levels. In post-day 3 CIT stimulated CH12F3 B cells, the AID gene 
expression in CH12F3 cells and WT splenocytes were at comparable levels (see 
Figure 34B). Despite similar UNG2 and AID in WT and CH12F3 cells, only 
stimulated CH12F3 cells accumulated uracils in their genome. Strikingly, in 
Ramos 1 cells transfected to express AID at higher levels, the expression of 
UNG2 increased but the uracil levels increased as well (Figure 45A and 47A). 
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4.1.4 Why does uracil accumulate despite presence of functional UNG2? 
 
 Several possibilities may explain the observed disconnect between the 
uracil excision activity of UNG2 and the accumulated genomic uracils in 
lymphomas. UNG2 is primarily involved in removing uracils incorporated during 
replication by polymerase utilization of dUTP to initiate canonical BER (see 
Figure 10) (181, 196).Thus, the involvement of UNG2 in promoting mutations and 
strand breaks in B cells may require specialized recruitment to the genes 
targeted by AID. The factors involved in successful recruitment involve specific 
chromatin modifications, post translational protein modifications, and the help of 
molecular chaperones. It is known that when the Ig locus undergoes SHM and 
CSR, the local chromatin undergoes specific epigenetic modifications (197), and 
a recruitment protein may bring UNG2 to the modified chromatin. Alternatively, 
since AID acts on transcribed genes (198), UNG may be associated or recruited 
with the transcription elongation complex. For example, Rev1, a TLS 
polymerase, has recently been shown to play a non-catalytic role in recruiting 
UNG2 to S regions specifically being targeted by AID during CSR (89). 
Additionally, specific phosphorylation of UNG2 may be involved in promoting its 
pro-mutagenic role in adaptive immunity (199). The accumulation of uracils in 
stimulated CH12F3 cells suggests that although UNG2 is present and nuclear 
excision activities are robust, one of these recruiting or modifying factors may be 
deregulated in lymphomas.  
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Figure 62. Ex Vivo Stimulation of Murine B Cells with LPS and IL-4
 
 
 
Figure 62. Ex Vivo Stimulation of Murine B Cells with LPS and IL-4.(A) AID 
expression following stimulation with LPS+IL-4. (B) UNG2 expression following 
stimulation with LPS+IL-4. (C) Genomic uracil levels following stimulation with 
LPS+IL-4 normalized to WT levels prior to stimulation. This figure was originally 
published in the supplementary material of (165). Reproduced from the American 
Society for Microbiology. 
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Figure 63. Homeostasis in Genomic Uracil Creation and Excision
 
 
 
Figure 63. Homeostasis in Genomic Uracil Creation and Excision. (Top 
panel) Homeostasis during normal B cell development in germinal centers. Uracil 
creation by AID and uracil excision by UNG2 are kept in balance during normal B 
cell-development, resulting in low genomic uracil levels. (Bottom panel) The 
balance between uracil creation and removal is lost during the development of 
pre-cancer B cells in favor of uracil creation. This is a “DNA repair crisis” for the 
precancerous cells leading to accumulation of mutations and strand breaks in 
addition to uracils and resulting in genomic instability. This may lead to cellular 
transformation. When uracil removal equalizes with uracil creation, stable 
lymphoma or leukemia cell lines are established. These cell lines maintain the 
high uracil levels introduced during the repair crisis. This figure was originally 
published in the supplementary material of (165). Reproduced from the American 
Society for Microbiology. 
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4.1.5 High yet Steady Levels of Uracils in Lymphoma Cell Lines 
 
 As noted before, the uracil levels in the Raji cell line do not greatly 
fluctuate over time (see Figure 43) suggesting that the high AID-dependent uracil 
levels are stable. One may predict that if AID continues to introduce genomic 
uracils with the levels continually rising in lymphomas, cells may develop 
deleterious genomic instability due to the accumulation of mutations and strand 
breaks. Therefore, this study suggests cell lines may only be able to be 
immortalized from high-AID expressing B lymphomas, if a balance between 
creation of genomic uracils and their excision is reached. This results in a new 
steady-state stable uracil level in the cell line. However, this cell line steady-state 
uracil level is higher than that found in normal B cells and does not represent 
homeostasis in genomic uracils.  
4.1.6 Possible DNA-repair Crisis disrupts Genomic Uracil Homeostasis 
 Increasing the expression of AID in B cell lymphomas or knocking it down 
results in increasing genomic uracils levels or decreasing them, respectively 
(Figure 45, 46, and 48). Drawing from these results, it is easy to envision some B 
cells lose the balance between uracil introduction and removal during the GC-
reaction possibly due to impaired targeting of UNG2 to uracils introduced by AID. 
This may result in an impaired ability to efficiently remove uracils created by AID 
in a timely manner resulting in a “DNA repair crisis” (Figure 63, lower panel). If 
this crisis persists it may result in high genomic instability, acquisition of 
mutations, and possible apoptosis if the cell cannot repair the damage effectively. 
However, during cell line establishment the uracil excision capabilities eventually 
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catch up with introduced uracils resulting in the establishment of a stable cell line. 
This results in a new steady-state condition where the genomic uracil levels are 
much higher than the level in unstimulated WT B cells (Figure 63, lower panel). 
In contrast, patients with B cell lymphomas/leukemias may still exhibit instability 
from this DNA repair crisis with no stability acquired in AID, UNG2, and genomic 
uracil levels. These levels may change overtime and under treatment and may 
differ among patients resulting in variation from cancer to cancer (Figure 49A and 
B).  
 An imbalance between AID creating uracils and UNG2 removing uracils in 
favor of AID would result in an increase in the frequency of base substitutions 
and mutations. In UNG-/- cells, the lacI and HPRT genes were shown to acquire 
mutations at 1.5 and 5-fold higher the rates found in normal cells respectively 
(196, 200). With the increased expression of AID upon B cell activation, any 
deficiency in UNG and thus uracil excision may increase mutations. If these 
mutations are in proto-oncogenes or tumor suppressors, lymphomagenesis may 
ensue. In fact, UNG-/- mice have been shown to develop B cell lymphomas 20-
fold higher than WT mice and have a shorter life expectancy (201). In addition, 
human follicular lymphomas have recently been shown to continually acquire AID 
dependent mutations in the variable region as well as non-Ig genes during the 
evolution of the patient’s cancer (128). Other members of the APOBEC family of 
proteins have also been implicated in promoting cancers and mutations. 
Sequencing of several tumor genomes has revealed these cancers accumulate 
mutations with an AID/APOBEC ‘signature.’ These include cancers originating in 
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the cervix, breast, and bladder, as well as of B cell origin (161, 162, 202). 
Furthermore, many breast cancer patient tumor samples and cell lines have been 
shown to overexpress APOBEC3B with at least two cell lines recently found to 
have elevated uracil levels (203). If the development of non-GC derived 
lymphomas overexpressing other APOBECs also involves the type of DNA repair 
crisis depicted in Figure 63, then an understanding of how the activation of 
normal B cells and their maturation may result in an imbalance between AID 
generated uracils and uracil excision by UNG2 may be critical to understanding 
how these cancers develop as well. 
4.2 AID-dependent Accumulation of Specific DNA Damage in B cell 
Lymphomas  
 
4.2.1 DNA damage caused by AID and UNG 
 
 This work has demonstrated that high-AID expressing cell lines 
accumulate large amounts of genomic uracil introduced by AID (165). 
Furthermore, the attempted repair of these uracils by UNG2 leads to a consistent 
pattern of AID expressing lymphomas accumulating high levels of DNA damage. 
The specific types of DNA lesions, including AP sites and strand breaks, are 
predicted to arise at each subsequent step of removal or attempted repair of 
uracils (see model presented in Figure 64). In fact, a reduction in UNG repair is 
met with a decrease in the downstream DNA lesions (AP sites and DSBs) in 
these high AID-expressing lymphomas. Another finding of this study is that 
inviable cells accumulate even more of the initial uracil lesion (Figure 57). This 
implicates that dead/dying cells may have overwhelming levels of uracils, 
possibly mutating genes essential to cell survival. These uracils continue to 
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accumulate and escape repair and may destine the cell to apoptose. Further 
studies are required to determine if the high uracil load signals programmed cell 
death. 
Figure 64. Model of DNA Damage Accumulation in High-AID Expressing 
Lymphomas 
 
 
Figure 64. Model of DNA Damage Accumulation in High-AID Expressing 
Lymphomas. AID introduces the initial uracil lesion. Uracils that escape repair or 
removal by such repair proteins as UNG2 accumulate throughout the genome. 
However, some uracils are recognized and excised by UNG2 producing higher 
than normal levels of AP sites in the DNA. The nicking of these sites by APE can 
lead to SSBs and eventually DSBs resulting in genomic instability and poor cell 
viability. Thus, this damage is dependent on AID and UNG. 
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4.2.2 Mechanism of Accumulated DNA damage in Lymphomas 
 
 The mammalian system is equipped with several repair mechanisms and 
enzymes to address uracils introduced in DNA. Four different glycosylases, 
UNG, TDG, MBD4, and SMUG1 (see TABLE 1) can excise uracils in DNA during 
base excision repair resulting in abasic sites. These AP sites can then be nicked 
by AP endonucleases (APE1/2) leading to single strand breaks and eventually 
double strand breaks. The increase in the number of AP sites observed in the 
genomes of these high-AID expressing cell lines may result from incomplete 
repair following excision by uracil glycosylases (see Figure 64). The 
accumulation of single- and double strand breaks may arise following incomplete 
repair of the nicking of these AP sites by APE. Furthermore, it is more likely that 
these DNA lesions are distributed at a large number of sites in the genome and 
not restricted to the Ig region, the major target of AID. When UNG is partially 
inhibited by expressing UGI, these cells accumulate higher uracil loads due to 
decreased repair abilities. However, less AP sites and DSBs are detected which 
supports the notion that these lesions arise in part, due to attempted removal by 
UNG. Cell viability, however, suffers with the reduction in repair in these high-AID 
expressing lymphomas. This may be caused by an increase in the mutational 
load of essential genes in the genomes due to escaped uracil repair that leads to 
interruptions in normal cell functions. 
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4.2.3 DNA Damage may promote Lymphomagenesis 
 
 It is well established that the translocation of c-myc, bcl-2, bcl-6 and other 
genes to the Ig gene loci are a hallmark of B cell malignancies (204). 
Additionally, in studies of B lymphocytes where translocations were induced by 
creating a designed break in the IgH or c-myc genes, the other break was 
created by AID and was found to lie at a large number of sites spread throughout 
the genome (205, 206). As AID is required for the translocation of the c-myc 
gene to the IgH locus (107), it is generally assumed that AID is involved in 
converting cytosines to uracils at these genes and that the newly introduced 
uracils are somehow converted to DSBs that are the cause of these 
translocations. It is attractive to suggest that the damage identified in this study is 
the source of DSBs that result in genome-wide translocations when AID is 
overexpressed in B lymphocytes (205, 206) including those that aid oncogenic 
transformation and lead to mutations in non-Ig genes (178). Like the 
accumulated uracils, future studies that determine the sequence of DNA 
fragments containing abasic sites and strand breaks found in these cancer 
genomes will clarify whether they are the direct cause of translocated genes 
found in these cells.  
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4.2.4 Future Directions 
 These findings point to new avenues for treating GC-derived lymphomas 
as these cells contain a large number of DNA modifications that are largely 
absent in normal cells. For example, once the mechanism underlying the 
observation that cells with higher uracils, AP sites, and strand breaks are prone 
to apoptose is better understood, it may be possible to exploit this phenomenon 
to selectively kill tumor cells highly expressing AID. For example, the 
accumulated types of DNA damage described here may be exacerbated by 
treatment with chemotherapeutic agents that lead to similar lesions. This may 
overwhelm the cells and result in cell arrest or death quicker or with lower doses 
of the chemotherapy since endogenous DNA damage persists already. In 
addition, the fact that B cell lymphomas accumulate uracils and therefore require 
functional BER for their removal and repair, it may make BER a target for 
chemotherapy. For example, methoxyamine, which is utilized in the uracil 
quantification assay to block endogenous abasic sites (see Figure 21), is also 
currently studied as part of a combination anticancer chemotherapy regimen 
when cancers are also treated with an alkylating agent such as Temozolomide 
(207). The alkylating agent promotes damage to the DNA bases that are then 
able to be excised by a DNA glycosylase resulting in AP sites. This allows Mx to 
react to these AP sites and therefore inhibits repair, leading to cell death. Several 
NCI-approved clinical trials using Mx in combination therapies are currently under 
investigation (NCT00892385, NCT01658319 and NCT00692159, 
clinicaltrials.gov). Since B cell lymphomas already have endogenous damage in 
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the form of high levels of uracils and AP sites this strategy may be worth 
investigating specifically in high-AID expressing B cell lymphomas as well as 
other high-APOBEC expressing cancers. In addition, other drugs that bind to AP 
sites and inhibit repair should also be considered. 
 The high accumulation of uracils in B cell cancers may also be used as a 
diagnostic marker for GC-derived lymphomas in addition to routine practices 
such as determining the cytogenetics and chromosomal abnormalities in the 
cancer. Furthermore, the accumulation of uracils and mutations should be 
explored as the possible cause for the common drug resistance observed in the 
treatment of some high-AID expressing cancers (208).  
 Future experiments need to be carried out to determine the molecular 
cause for the imbalance seen in uracil accumulation and excision in lymphomas. 
For example, UNG2 is present and active in these cells at normal or above 
noraml levels. Thus, it is possible that deregulation of recruitment of UNG2 to the 
AID-generated uracils is the culprit. 
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ABSTRACT 
THE LOSS OF GENOMIC URACIL HOMEOSTASIS AND AID-DEPENDENT 
ACCUMULATION OF DNA DAMAGE IN B CELL LYMPHOMAS 
by 
SOPHIA SHALHOUT 
May 2015 
Advisor: Dr. Ashok S. Bhagwat 
Major: Chemistry (Biochemistry) 
Degree: Doctor of Philosophy 
 Activation-induced deaminase (AID) is a sequence-selective DNA cytosine 
deaminase that introduces uracils in immunoglobulin genes. This DNA mutator is 
required for somatic hypermutation and class switch recombination- processes 
involved in the affinity maturation and diversification of antibodies. AID, however, 
can also lead to deleterious mutations and translocations promoting 
lymphomagenesis. The introduction of uracils throughout the genome of 
activated B cells and the ability of UNG2 glycosylase to excise these uracils is 
examined here. This interplay was also studied in cancerous B cells, with 
different results emerging in transformed cells versus healthy cells. Genomic 
uracil levels are found to remain at the same level in normal B cells stimulated to 
express AID. However the increase in uracils by 11- to 60- fold detected in 
stimulated B cells deficient in UNG, suggests that normal B cells do accumulate 
high levels of genomic uracils. However, these uracils are efficiently and 
effectively removed in UNG proficient cells, suggesting a balance or homeostasis 
between uracil creation and elimination. Interestingly, murine B cell cancer lines, 
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human B cell cancer cell lines, and several human B cell patient tumors from 
several types of lymphomas overexpressing AID, were found to accumulate 
genomic uracils at levels comparable to those seen in activated UNG-/- B cells. 
These lymphoma/leukemia cells are not defective in uracil removal and express 
UNG2 gene at the same level in normal peripheral B cells or higher. In addition, 
they also have similar nuclear uracil excision activities suggesting uracils 
accumulate despite robust uracil excision capabilities. These results suggest that 
the homeostasis of uracil introduction and excision seen in normal stimulated B 
cells is disrupted in lymphomas overexpressing AID despite UNG2 expression 
and activity, resulting in the accumulation of high levels of genome wide uracils. 
 The majority of human B cell lymphomas do in fact derive from cells that 
have undergone the germinal center reaction and are associated with the 
expression of AID. The high levels of uracils that accumulate in the genomes of B 
cell lymphomas suggests other types of DNA damage may also be present in an 
AID-dependent manner as the cell attempts to remove and repair these uracils. 
Here, we see that human B cell lymphoma cell lines that contain high uracil loads 
also accumulate elevated levels of other types of genome wide DNA damage 
dependent on AID. These include abasic sites and single- and double-strand 
breaks. In addition, the accumulation of DNA lesions reduces cell viability. These 
lesions are due in part to the attempted repair of uracils by uracil DNA 
glycosylase. 
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B.S.          Biological Sciences                                                            2009 
                 Wayne State University, Detroit, Michigan 
 
 
Publications 
 
Shalhout, S., Haddad, D., Sosin A.,, Holland, T., Al-Katib, A., Martin, A., Bhagwat, A. S. 
(2014). Genomic Uracil Homeostasis during Normal B Cell Maturation and Loss of this 
Balance During B Cell Cancer Development. Molecular and Cellular Biology. 
34(21):4019-32. 
 
Shalhout, S.*, Betham, B.*, Marquez, V.E., Bhagwat, A.S. (2010). Use of Drosophila 
deoxynucleoside kinase to study mechanism of toxicity and mutagenicity of 
deoxycytidine analogs in Escherichia coli. DNA Repair 9, 153-160. *co-first authors 
 
Wei S, Shalhout S, Ahn Y-H, Bhagwat AS. (2015) A Versatile New Tool to Label Abasic 
Sites in DNA and Inhibit Base Excision Repair. DNA Repair, 27, 9-18. 
 
Shalhout, S., Haddad, D., Martin, A., Bhagwat, A. S. Multiple Types of DNA Damage in 
Germinal Center-derived Human B cell Lymphomas Expressing AID. (manuscript 
submitted and under review) 
 
Scholarships & Awards 
 
Summer Dissertation Fellowship Award 2013-2014 
Paul C. Schaap-Rumble Graduate Professional Research Fellowship 2013-2014 
Biological Chemistry Outstanding Graduate Student Award  2013 
Graduate and Professional Student Travel Award 2013 
Willard R. Lenz Memorial Fellowship  2012 
Chemistry Department (WSU) Award for Excellence in Teaching 2011  
Chemistry Department (WSU) Award for Excellence in Service  2011 
Thomas C. Rumble Fellowship  2012 
Herbert K. Livingston Award for Excellence in Teaching  2010-2011 
Chemistry Department (WSU) Award for Excellence in Teaching  2009 
Presidential Scholarship, WSU  2004 
Michigan Competitive Scholarship 2004 
